Maravai LifeSciences (MRVI) 10-Q 5 Aug 22 2022 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2022	Jul. 29, 2022
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2022
Document Transition Report	false
Entity File Number	001-39725
Entity Registrant Name	Maravai LifeSciences Holdings, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	85-2786970
Entity Address, Address Line One	10770 Wateridge Circle
Entity Address, Address Line Two	Suite 200
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92121
City Area Code	858
Local Phone Number	546-0004
Title of 12(b) Security	Class A common stock, $0.01 par value
Trading Symbol	MRVI
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Central Index Key	0001823239
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Amendment Flag	false
Class A Common Stock
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		131,539,642
Class B Common Stock
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		123,669,196

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash	$ 550,676	$ 551,272
Accounts receivable, net	120,354	117,512
Inventory	60,113	51,557
Prepaid expenses and other current assets	19,664	19,698
Government funding receivable	8,575	0
Total current assets	759,382	740,039
Property and equipment, net	46,956	46,332
Goodwill	283,535	152,766
Intangible assets, net	229,153	117,571
Deferred tax assets	780,354	808,117
Other assets	72,419	53,451
Total assets	2,171,799	1,918,276
Current liabilities:
Accounts payable	23,267	8,154
Accrued expenses and other current liabilities	43,641	34,574
Deferred revenue	5,435	10,211
Current portion of payable to related parties pursuant to a Tax Receivable Agreement	34,747	34,838
Current portion of long-term debt	5,440	6,000
Total current liabilities	112,530	93,777
Long-term debt, less current portion	523,655	524,591
Payable to related parties pursuant to a Tax Receivable Agreement, less current portion	711,232	713,481
Other long-term liabilities	50,590	41,066
Total liabilities	1,398,007	1,372,915
Stockholders' equity:
Additional paid-in capital	131,373	128,386
Retained earnings	322,663	184,561
Total stockholders' equity attributable to Maravai LifeSciences Holdings, Inc.	456,588	315,499
Non-controlling interest	317,204	229,862
Total stockholders' equity	773,792	545,361
Total liabilities and stockholders' equity	2,171,799	1,918,276
Class A Common Stock
Stockholders' equity:
Common stock	1,315	1,315
Class B Common Stock
Stockholders' equity:
Common stock	$ 1,237	$ 1,237

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares shares in Thousands	Jun. 30, 2022	Dec. 31, 2021
Class A Common Stock
Common stock, par value (in usd per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	500,000	500,000
Common stock, shares issued (in shares)	131,539	131,488
Common stock, shares outstanding (in shares)	131,539	131,488
Class B Common Stock
Common stock, par value (in usd per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	300,000	300,000
Common stock, shares issued (in shares)	123,669	123,669
Common stock, shares outstanding (in shares)	123,669	123,669

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	[1]	Jun. 30, 2022	Jun. 30, 2021	[1]
Income Statement [Abstract]
Revenue	$ 242,732	$ 217,775		$ 487,025	$ 365,986
Operating expenses:
Cost of revenue	37,496	37,811		77,528	69,202
Selling, general and administrative	28,061	24,500		61,261	47,971
Research and development	4,274	1,929		7,969	4,089
Change in estimated fair value of contingent consideration	(7,800)	0		(7,800)	0	[2]
Total operating expenses	62,031	64,240		138,958	121,262
Income from operations	180,701	153,535		348,067	244,724
Other income (expense):
Interest expense	(4,434)	(7,649)		(7,098)	(15,553)
Loss on extinguishment of debt	0	0		(208)	0	[2]
Change in payable to related parties pursuant to a Tax Receivable Agreement	0	0		2,340	5,886
Other expense	(1,275)	(3)		(1,268)	0
Income before income taxes	174,992	145,883		341,833	235,057
Income tax expense	18,271	11,386		38,252	25,095
Net income	156,721	134,497	[3]	303,581	209,962	[2]
Net income attributable to non-controlling interests	85,481	85,354		165,479	137,717
Net income attributable to Maravai LifeSciences Holdings, Inc.	$ 71,240	$ 49,143		$ 138,102	$ 72,245
Net income per Class A common share attributable to Maravai LifeSciences Holdings, Inc.:
Basic (in usd per share)	$ 0.54	$ 0.44		$ 1.05	$ 0.69
Diluted (in usd per share)	$ 0.53	$ 0.44		$ 1.03	$ 0.69
Weighted average number of Class A common shares outstanding:
Basic (in shares)	131,524	112,203		131,506	104,468
Diluted (in shares)	255,361	112,280		255,324	257,686
[1]As adjusted to reflect the impact of the adoption of Accounting Standards Codification 842 (“ASC 842”). See Note 1 to the condensed consolidated financial statements for a summary of the adjustments.[2]As adjusted to reflect the impact of the adoption of ASC 842. See Note 1 to the condensed consolidated financial statements for a summary of the adjustments.[3]As adjusted to reflect the impact of the adoption of ASC 842. See Note 1 to the condensed consolidated financial statements for a summary of the adjustments.

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	[1]	Jun. 30, 2022	Jun. 30, 2021
Statement of Comprehensive Income [Abstract]
Net income	$ 156,721	$ 134,497	[2]	$ 303,581	$ 209,962	[2],[3]
Other comprehensive income:
Foreign currency translation adjustments	0	8		0	16	[1]
Total other comprehensive income	156,721	134,505		303,581	209,978	[1]
Comprehensive income attributable to non-controlling interests	85,481	85,359		165,479	137,728	[1]
Total comprehensive income attributable to Maravai LifeSciences Holdings, Inc.	$ 71,240	$ 49,146		$ 138,102	$ 72,250	[1]
[1]As adjusted to reflect the impact of the adoption of ASC 842. See Note 1 to the condensed consolidated financial statements for a summary of the adjustments.[2]As adjusted to reflect the impact of the adoption of Accounting Standards Codification 842 (“ASC 842”). See Note 1 to the condensed consolidated financial statements for a summary of the adjustments.[3]As adjusted to reflect the impact of the adoption of ASC 842. See Note 1 to the condensed consolidated financial statements for a summary of the adjustments.

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total		Cumulative Effect, Period of Adoption, Adjustment	Common Stock Class A Common Stock		Common Stock Class B Common Stock		Additional Paid-In Capital		Accumulated Other Comprehensive Loss		Retained Earnings		Retained Earnings Cumulative Effect, Period of Adoption, Adjustment	Non-Controlling Interest		Non-Controlling Interest Cumulative Effect, Period of Adoption, Adjustment
Beginning balance (in shares) at Dec. 31, 2020				96,647		160,974
Beginning balance at Dec. 31, 2020	$ 154,746		$ 4,454	$ 966		$ 1,610		$ 85,125		$ (44)		$ 854		$ 1,670	$ 66,235		$ 2,784
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Effect of exchange of LLC Units (in shares)				17,666		(17,666)
Effect of exchange of LLC Units	0			$ 177		$ (177)		12,129							(12,129)
Recognition of impact of Tax Receivable Agreement due to exchanges of LLC Units	18,940							18,940
Issuance of Class A common stock under employee equity plans, net of shares withheld for employee taxes (in shares)				39
Issuance of Class A common stock under employee equity plans, net of shares withheld for employee taxes	785							785
Non-controlling interest adjustment for changes in proportionate ownership in Topco LLC	0							(420)							420
Stock-based compensation	4,661							1,893							2,768
Distribution for tax liabilities to non-controlling interest holder	(56,203)							34							(56,237)
Net income	209,962	[1],[2]										72,245			137,717
Foreign currency translation adjustments	16	[3]								5					11
Ending balance (in shares) at Jun. 30, 2021				114,352	[4]	143,308	[5]
Ending balance at Jun. 30, 2021	337,361	[5]		$ 1,143	[5]	$ 1,433	[4]	118,486	[5]	(39)	[5]	74,769	[4]		141,569	[4]
Beginning balance (in shares) at Mar. 31, 2021				96,647		160,974
Beginning balance at Mar. 31, 2021	213,823			$ 966		$ 1,610		85,976		(42)		25,626			99,687
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Effect of exchange of LLC Units (in shares)				17,666		(17,666)
Effect of exchange of LLC Units	0			$ 177		$ (177)		12,129							(12,129)
Recognition of impact of Tax Receivable Agreement due to exchanges of LLC Units	18,940							18,940
Issuance of Class A common stock under employee equity plans, net of shares withheld for employee taxes (in shares)				39
Issuance of Class A common stock under employee equity plans, net of shares withheld for employee taxes	785							785
Non-controlling interest adjustment for changes in proportionate ownership in Topco LLC	0							(420)							420
Stock-based compensation	2,383							1,039							1,344
Distribution for tax liabilities to non-controlling interest holder	(33,075)							37							(33,112)
Net income	134,497	[2],[3]										49,143			85,354
Foreign currency translation adjustments	8	[3]								3					5
Ending balance (in shares) at Jun. 30, 2021				114,352	[4]	143,308	[5]
Ending balance at Jun. 30, 2021	337,361	[5]		$ 1,143	[5]	$ 1,433	[4]	118,486	[5]	$ (39)	[5]	74,769	[4]		141,569	[4]
Beginning balance (in shares) at Dec. 31, 2021				131,488		123,669
Beginning balance at Dec. 31, 2021	545,361			$ 1,315		$ 1,237		128,386				184,561			229,862
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of Class A common stock under employee equity plans, net of shares withheld for employee taxes (in shares)				51
Issuance of Class A common stock under employee equity plans, net of shares withheld for employee taxes	1,148							1,148
Non-controlling interest adjustment for changes in proportionate ownership in Topco LLC	0							(494)							494
Stock-based compensation	7,935							4,089							3,846
Distribution for tax liabilities to non-controlling interest holder	(82,542)							(65)							(82,477)
Impact of change to deferred tax asset associated with cash contribution to Topco LLC	(1,691)							(1,691)
Net income	303,581											138,102			165,479
Foreign currency translation adjustments	0
Ending balance (in shares) at Jun. 30, 2022				131,539		123,669
Ending balance at Jun. 30, 2022	773,792			$ 1,315		$ 1,237		131,373				322,663			317,204
Beginning balance (in shares) at Mar. 31, 2022				131,490		123,669
Beginning balance at Mar. 31, 2022	654,302			$ 1,315		$ 1,237		128,584				251,423			271,743
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of Class A common stock under employee equity plans, net of shares withheld for employee taxes (in shares)				49
Issuance of Class A common stock under employee equity plans, net of shares withheld for employee taxes	1,114							1,114
Non-controlling interest adjustment for changes in proportionate ownership in Topco LLC	0							(480)							480
Stock-based compensation	4,308							2,220							2,088
Distribution for tax liabilities to non-controlling interest holder	(42,653)							(65)							(42,588)
Net income	156,721											71,240			85,481
Foreign currency translation adjustments	0
Ending balance (in shares) at Jun. 30, 2022				131,539		123,669
Ending balance at Jun. 30, 2022	$ 773,792			$ 1,315		$ 1,237		$ 131,373				$ 322,663			$ 317,204
[1]As adjusted to reflect the impact of the adoption of ASC 842. See Note 1 to the condensed consolidated financial statements for a summary of the adjustments.[2]As adjusted to reflect the impact of the adoption of Accounting Standards Codification 842 (“ASC 842”). See Note 1 to the condensed consolidated financial statements for a summary of the adjustments.[3]As adjusted to reflect the impact of the adoption of ASC 842. See Note 1 to the condensed consolidated financial statements for a summary of the adjustments.[4]As adjusted to reflect the impact of the adoption of ASC 842. See Note 1 to the condensed consolidated financial statements for a summary of the adjustments.[5]As adjusted to reflect the impact of the adoption of ASC 842. See Note 1 to the condensed consolidated financial statements for a summary of the adjustments.

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	[1]
Operating activities:
Net income	$ 303,581	$ 209,962	[2]
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	3,747	2,871
Amortization of intangible assets	11,779	10,081
Amortization of right-of-use assets	2,639	3,510
Amortization of deferred financing costs	1,410	1,319
Stock-based compensation expense	7,935	4,661
Loss on extinguishment of debt	208	0	[2]
Deferred income taxes	26,073	18,211
Change in estimated fair value of contingent consideration	(7,800)	0	[2]
Revaluation of liabilities under the Tax Receivable Agreement	(2,340)	(5,886)
Other	(1,283)	(101)
Changes in operating assets and liabilities:
Accounts receivable	(2,332)	(36,471)
Inventory	(7,502)	(18,494)
Prepaid expenses and other assets	(10,052)	(5,070)
Accounts payable	6,310	4,161
Accrued expenses and other current liabilities	(1,773)	(12,544)
Deferred revenue	(4,776)	31,430
Other long-term liabilities	759	(3,375)
Net cash provided by operating activities	326,583	204,265
Investing activities:
Cash paid for acquisition of a business, net of cash acquired	(238,836)	0
Purchases of property and equipment	(4,409)	(7,865)
Proceeds from sale of building	0	548
Net cash used in investing activities	(243,245)	(7,317)
Financing activities:
Distributions for tax liabilities to non-controlling interests holders	(82,477)	(56,203)
Proceeds from borrowings of long-term debt	8,455	0
Principal repayments of long-term debt	(11,175)	(3,000)
Proceeds from employee stock purchase plan and exercise of stock options, net of shares withheld for employee taxes	1,263	1,018
Net cash used in financing activities	(83,934)	(58,185)
Effects of exchange rate changes on cash	0	13
Net (decrease) increase in cash including cash classified within current assets held for sale	(596)	138,776
Less: Net increase in cash classified within current assets held for sale	0	(250)
Net (decrease) increase in cash	(596)	138,526
Cash, beginning of period	551,272	236,184
Cash, end of period	550,676	374,710
Supplemental cash flow information:
Cash paid for interest	6,132	13,972
Cash paid for income taxes	13,856	9,087
Supplemental disclosures of non-cash investing and financing activities:
Property and equipment included in accounts payable and accrued expenses	2,145	1,035
Right-of-use assets obtained in exchange for new operating lease liabilities	773	0
Fair value of contingent consideration liability recorded in connection with acquisition of a business	7,800	0	[2]
Accrued consideration payable	10,000	0
Recognition of liabilities under the Tax Receivable Agreement	0	137,706
Recognition of deferred tax assets as a result of exchange of LLC Units	$ 0	$ 156,647
[1]As adjusted to reflect the impact of the adoption of ASC 842. See Note 1 to the condensed consolidated financial statements for a summary of the adjustments.[2]As adjusted to reflect the impact of the adoption of Accounting Standards Codification 842 (“ASC 842”). See Note 1 to the condensed consolidated financial statements for a summary of the adjustments.

Organization and Significant Ac

Organization and Significant Accounting Policies	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Significant Accounting Policies	Organization and Significant Accounting Policies Description of Business Maravai LifeSciences Holdings, Inc. (the “Company”, and together with its consolidated subsidiaries, “Maravai”, “we”, “us”, and “our”) provides critical products to enable the development of drugs, therapeutics, diagnostics and vaccines and to support research on human diseases. Our products address the key phases of biopharmaceutical development and include complex nucleic acids for diagnostic and therapeutic applications and antibody-based products to detect impurities during the production of biopharmaceutical products. The Company is headquartered in San Diego, California and has historically operated in three principal businesses: Nucleic Acid Production, Biologics Safety Testing and Protein Detection. In September 2021, the Company completed the divestiture of its Protein Detection business. Our Nucleic Acid Production business manufactures and sells products used in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling and purification of deoxyribonucleic acid (“DNA”) and ribonucleic acid (“RNA”). Our core Nucleic Acid Production offerings include messenger ribonucleic acid (“mRNA”), long and short oligonucleotides, our proprietary CleanCap® capping technology and oligonucleotide building blocks. Our Biologics Safety Testing business sells highly specialized analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. Organization We were incorporated as a Delaware corporation in August 2020 for the purpose of facilitating an initial public offering (“IPO”). Immediately prior to the IPO, we effected a series of organizational transactions (the “Organizational Transactions”), which, together with the IPO, were completed in November 2020, that resulted in the Company operating, controlling all of the business affairs and becoming the ultimate parent company of Maravai Topco Holdings, LLC (“Topco LLC”) and its consolidated subsidiaries. Maravai Life Sciences Holdings, LLC (“MLSH 1”), which is controlled by investment entities affiliated with GTCR, is the only other member of Topco LLC. The Company is the sole managing member of Topco LLC, which operates and controls TriLink Biotechnologies, LLC (“TriLink”), Glen Research, LLC, MockV Solutions, LLC and Cygnus Technologies, LLC (“Cygnus”) and their respective subsidiaries. Prior to the Company’s divestiture of its Protein Detection business in September 2021, Topco LLC also operated and controlled Vector Laboratories, Inc. and its subsidiaries (“Vector”). Basis of Presentation The Company operates and controls all of the business and affairs of Topco LLC, and through Topco LLC and its subsidiaries, conducts its business. Because we manage and operate the business and control the strategic decisions and day-to-day operations of Topco LLC and also have a substantial financial interest in Topco LLC, we consolidate the financial results of Topco LLC, and a portion of our net income is allocated to the non-controlling interests in Topco LLC held by MLSH 1. The accompanying unaudited interim condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany transactions and accounts between the businesses comprising the Company have been eliminated in the accompanying consolidated financial statements. Unaudited Interim Condensed Consolidated Financial Statements The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and pursuant to Form 10-Q of Regulation S-X of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These unaudited condensed consolidated financial statements include all adjustments necessary to fairly state the financial position and the results of our operations and cash flows for interim periods in accordance with GAAP. All such adjustments are of a normal, recurring nature. Operating results for the three and six months ended June 30, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022 or for any future period. The condensed consolidated balance sheet presented as of December 31, 2021, has been derived from the audited consolidated financial statements as of that date. The condensed consolidated financial statements and notes are presented as permitted by Form 10-Q and do not contain all information that is included in the annual financial statements and notes thereto of the Company. The condensed consolidated financial statements and notes included in this report should be read in conjunction with the consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 (“2021 Form 10-K”) filed with the SEC. Use of Estimates The preparation of consolidated financial statements in accordance with GAAP requires the Company to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenue and expenses, and related disclosures. These estimates form the basis for judgments the Company makes about the carrying values of assets and liabilities that are not readily apparent from other sources. The Company bases its estimates and judgments on historical experience and on various other assumptions that the Company believes are reasonable under the circumstances. These estimates are based on management’s knowledge about current events and expectations about actions the Company may undertake in the future. Significant estimates include, but are not limited to the payable to related parties pursuant to the Tax Receivable Agreement (as defined in Note 10), the realizability of our net deferred tax assets, and valuation of goodwill and intangible assets acquired in business combinations. Actual results could differ materially from those estimates. Significant Accounting Policies A description of the Company’s significant accounting policies is included in Note 1 of the Notes to the Consolidated Financial Statements included in its 2021 Form 10-K. Except as noted below, there have been no material changes in the Company’s significant accounting policies during the three and six months ended June 30, 2022. Revenue Recognition The Company generates revenue primarily from the sale of products, and to a much lesser extent, services in the fields of nucleic acid production, biologics safety testing and protein detection. Revenue is recognized when control of promised goods or services is transferred to a customer in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for its arrangements with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The majority of the Company’s contracts include only one performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is defined as the unit of account for revenue recognition. The Company also recognizes revenue from other contracts that may include a combination of products and services, the provision of solely services, or from license fee arrangements which may be associated with the delivery of product. Where there is a combination of products and services, the Company accounts for the promises as individual performance obligations if they are concluded to be distinct. Performance obligations are considered distinct if they are both capable of being distinct and distinct within the context of the contract. In determining whether performance obligations meet the criteria for being distinct, the Company considers a number of factors, such as the degree of interrelation and interdependence between obligations, and whether or not the good or service significantly modifies or transforms another good or service in the contract. As a practical expedient, we do not adjust the transaction price for the effects of a significant financing component if, at contract inception, the period between customer payment and the transfer of goods or services is expected to be one year or less. Contracts with customers are evaluated on a contract-by-contract basis as contracts may include multiple types of goods and services as described below. Nucleic Acid Production Nucleic Acid Production revenue is generated from the manufacture and sale of highly modified, complex nucleic acids products to support the needs of our of customers’ research, therapeutic and vaccine programs. The primary offering of products includes CleanCap®, mRNA and specialized oligonucleotides. Contracts typically consist of a single performance obligation. We also sell nucleic acid products for labeling and detecting proteins in cells and tissue samples research. The Company recognizes revenue from these products in the period in which the performance obligation is satisfied by transferring control to the customer. Revenue for nucleic acid catalog products is recognized at a single point in time, generally upon shipment to the customer. Revenue for contracts for certain custom nucleic acid products, with an enforceable right to payment and a reasonable margin for work performed to date, is recognized over time, based on a cost-to-cost input method over the manufacturing period. Payments received from customers in advance of manufacturing their products is recorded as deferred revenue until the products were delivered. Biologics Safety Testing The Company’s Biologics Safety Testing revenue is associated with the sale of bioprocess impurity detection kit products. We also enter into contracts that include custom antibody development, assay development and antibody affinity extraction services. These products and services enable the detection of impurities that occur in the manufacturing of biologic drugs and other therapeutics. The Company recognizes revenue from the sale of bioprocess impurity detection kits in the period in which the performance obligation is satisfied by transferring control to the customer. Custom antibody development contracts consist of a single performance obligation, typically with an enforceable right to payment and a reasonable margin for work performed to date. Revenue is recognized over time based on a cost-to-cost input method over the contract term. Where an enforceable right to payment does not exist, revenue is recognized at a point in time when control is transferred to the customer. Assay development service contracts consist of a single performance obligation, revenue is recognized at a point in time when a successful antigen test and report is provided to the customer. Affinity extraction services, which generally occur over a short period of time, consist of a single performance obligation to perform the extraction service and provide a summary report to the customer. Revenue is recognized either over time or at a point in time depending on contractual payment terms with the customer. Protein Detection Prior to the divestiture of its Protein Detection business in September 2021, the Company also manufactured and sold protein labeling and detection reagents to customers that were used for basic research and development. The contracts to sell these catalog products consisted of a single performance obligation to deliver the reagent products. Revenue from these contracts was recognized at a point in time, generally upon shipment of the final product to the customer. The Company elected the practical expedient to not disclose the unfulfilled performance obligations for contracts with an original length of one year or less. The Company had no material unfulfilled performance obligations for contracts with an original length greater than one year for any period presented. The Company accepts returns only if the products do not meet customer specifications and historically, the Company’s volume of product returns has not been significant. Further, no warranties are provided for promised goods and services other than assurance type warranties. Revenue for an individual contract is recognized at the related transaction price, which is the amount the Company expects to be entitled to in exchange for transferring the products and/or services. The transaction price for product sales is calculated at the contracted product selling price. The transaction price for a contract with multiple performance obligations is allocated to the separate performance obligations on a relative standalone selling price basis. Standalone selling prices for products are determined based on the prices charged to customers, which are directly observable. Standalone selling price of services are mostly based on time and materials. Generally, payments from customers are due when goods and services are transferred. As most contracts contain a single performance obligation, the transaction price is representative of the standalone selling price charged to customers. Revenue is recognized only to the extent that it is probable that a significant reversal of the cumulative amount recognized will not occur in future periods. Variable consideration has not been material to our consolidated financial statements. Sales taxes Sales taxes collected by the Company are not included in the transaction price as revenue as they are ultimately remitted to a governmental authority. Shipping and handling costs The Company has elected to account for shipping and handling activities related to contracts with customers as costs to fulfill the promise to transfer the associated products. Accordingly, revenue for shipping and handling is recognized at the same time that the related product revenue is recognized. Contract costs The Company recognizes the incremental costs of obtaining contracts as an expense when incurred when the amortization period of the assets that otherwise would have been recognized is one year or less. These costs are included in sales and marketing and general and administrative expenses. The costs to fulfill the contracts are determined to be immaterial and are recognized as an expense when incurred. Contract balances Contract assets are generated when contractual billing schedules differ from revenue recognition timing and the Company records a contract receivable when it has an unconditional right to consideration. There were no contract asset balances as of June 30, 2022 and December 31, 2021. Contract liabilities include billings in excess of revenue recognized, such as customer deposits and deferred revenue. Customer deposits, which are included in accrued expenses, are recorded when cash payments are received or due in advance of performance. Deferred revenue is recorded when the Company has unsatisfied performance obligations. Total contract liabilities were $7.5 million and $12.6 million as of June 30, 2022 and December 31, 2021, respectively. Contract liabilities are expected to be recognized into revenue within the next twelve months. Disaggregation of Revenue The following tables summarize the revenue by segment and region for the periods presented (in thousands): Three Months Ended June 30, 2022 Nucleic Acid Production Biologics Safety Testing Total North America $ 82,015 $ 7,172 $ 89,187 Europe, the Middle East and Africa 113,461 4,578 118,039 Asia Pacific 29,737 5,605 35,342 Latin and Central America 35 129 164 Total revenue $ 225,248 $ 17,484 $ 242,732 Six Months Ended June 30, 2022 Nucleic Acid Production Biologics Safety Testing Total North America $ 161,433 $ 14,691 $ 176,124 Europe, the Middle East and Africa 244,811 9,275 254,086 Asia Pacific 42,604 13,933 56,537 Latin and Central America 50 228 278 Total revenue $ 448,898 $ 38,127 $ 487,025 Three Months Ended June 30, 2021 Nucleic Acid Production Biologics Safety Testing Protein Detection Total North America $ 65,715 $ 6,437 $ 4,197 $ 76,349 Europe, the Middle East and Africa 106,046 3,899 1,892 111,837 Asia Pacific 20,760 7,668 913 29,341 Latin and Central America — 204 44 248 Total revenue $ 192,521 $ 18,208 $ 7,046 $ 217,775 Six Months Ended June 30, 2021 Nucleic Acid Production Biologics Safety Testing Protein Detection Total North America $ 133,847 $ 12,849 $ 7,949 $ 154,645 Europe, the Middle East and Africa 153,944 8,248 3,360 165,552 Asia Pacific 28,645 14,403 2,273 45,321 Latin and Central America 17 357 94 468 Total revenue $ 316,453 $ 35,857 $ 13,676 $ 365,986 Total revenue is attributed to geographic regions based on the bill-to location of the transaction. For all periods presented, the majority of our revenue was recognized at a point in time. Non-Controlling Interests Non-controlling interests represent the portion of profit or loss, net assets and comprehensive income of our consolidated subsidiaries that is not allocable to the Company based on our percentage of ownership of such entities. In November 2020, following the completion of the Organizational Transactions, we became the sole managing member of Topco LLC. As of June 30, 2022, we held approximately 51.5% of the outstanding LLC Units of Topco LLC, and MLSH 1 held approximately 48.5% of the outstanding LLC Units of Topco LLC. Therefore, we report non-controlling interests based on the percentage of LLC Units of Topco LLC held by MLSH 1 on the condensed consolidated balance sheet as of June 30, 2022. Income or loss attributed to the non-controlling interest in Topco LLC is based on the LLC Units outstanding during the period for which the income or loss is generated and is presented on the condensed consolidated statements of income and condensed consolidated statements of comprehensive income. MLSH 1 is entitled to exchange its LLC Units of Topco LLC, together with an equal number of shares of our Class B common stock (together referred to as “Paired Interests”), for shares of Class A common stock on a one-for-one basis or, at our election, for cash, from a substantially concurrent public offering or private sale (based on the price of our Class A common stock in such public offering or private sale). As such, future exchanges of Paired Interests by MLSH 1 will result in a change in ownership and reduce or increase the amount recorded as non-controlling interests and increase or decrease additional paid-in-capital when Topco LLC has positive or negative net assets, respectively. In April 2021, MLSH 1 executed an exchange of Paired Interests prior to the April 2021 Secondary Offering. For the six months ended June 30, 2022, MLSH 1 did not exchange any Paired Interests. Exchange and Secondary Offering In April 2021, MLSH 1 executed an exchange of 17,665,959 LLC Units (paired with the corresponding shares of Class B common stock) in return for 17,665,959 shares of the Company’s Class A common stock. The corresponding shares of Class B common stock were subsequently cancelled and retired. The Company immediately completed a secondary offering (“April 2021 Secondary Offering”) of 20,700,000 shares of its Class A common stock by MLSH 1 and MLSH 2, which included 3,034,041 shares of Class A common stock previously held by MLSH 2, which included the full exercise of the underwriters’ option to purchase up to 2,700,000 additional shares of Class A common stock, at a price of $31.25 per share. The selling stockholders were responsible for the underwriting discounts and commissions of the April 2021 Secondary Offering and received all of the net proceeds of $624.2 million from the sale of shares of Class A common stock. The Company was responsible for the offering costs associated with the April 2021 Secondary Offering of $1.0 million which were recorded within selling, general and administrative in the condensed consolidated statements of income. Distributions of $42.6 million and $82.5 million for tax liabilities were made to MLSH 1 during the three and six months ended June 30, 2022, respectively. Distributions of $33.1 million and $56.2 million for tax liabilities were made to MLSH 1 during the three and six months ended June 30, 2021, respectively. Segment Information The Company has historically operated in three reportable segments. Operating segments are defined as components of an enterprise for which separate financial information is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and assessing performance. The Company’s chief operating decision maker (“CODM”), its Chief Executive Officer, allocates resources and assesses performance based upon discrete financial information at the segment level. All of our long-lived assets are located in the United States. After the divestiture of Vector in September 2021, the Company no longer has the Protein Detection segment. The Company has reported the historical results of the Protein Detection business as such discrete financial information evaluated by the CODM for the periods presented included the information for this legacy segment. As of June 30, 2022, the Company operated in two reportable segments: Nucleic Acid Production and Biologics Safety Testing. Net Income per Class A Common Share Attributable to Maravai LifeSciences Holdings, Inc. Basic net income per Class A common share attributable to Maravai LifeSciences Holdings, Inc. is computed by dividing net income attributable to us by the weighted average number of Class A common shares outstanding during the period. Diluted net income per Class A common share is calculated by giving effect to all potential weighted average dilutive stock options, restricted stock units, and Topco LLC Units, that together with an equal number of shares of our Class B common stock , are convertible into shares of our Class A common stock. The dilutive effect of outstanding awards, if any, is reflected in diluted earnings per share by application of the treasury stock method or if-converted method, as applicable. The Company reported net income attributable to Maravai LifeSciences Holdings, Inc. for the three and six months ended June 30, 2022 and 2021. Government Assistance The consideration awarded to the Company by the U.S. Department of Defense is outside the scope of the contracts with customers, income tax, funded research and development, and contribution guidance. This is because the awarding entity is not considered to be a customer, the receipt of the funding is not predicated on the Company’s income tax position, there are no refund provisions, and the entity is not receiving reciprocal value for their support provided to the Company. The Company’s elected policy is to recognize such assistance as a reduction to the carrying amount of the assets associated with the award when it is reasonably assured that the funding will be received as evidenced through the existence of an arrangement, amounts eligible for reimbursement are determinable and have been incurred or paid, the applicable conditions under the arrangement have been met, and collectability of amounts due is reasonably assured. Contingent Consideration Contingent consideration represents additional consideration that may be transferred to former owners of an acquired entity in the future if certain future events occur or conditions are met. Contingent consideration resulting from the acquisition of a business is recorded at fair value on the acquisition date. Such contingent consideration is re-measured to its estimated fair value at each reporting date with the change in fair value recognized within operating expenses in the Company’s condensed consolidated statements of income. Subsequent changes in the fair value of the contingent consideration are classified as an adjustment to cash flows from operating activities in the condensed consolidated statements of cash flows because the change in fair value is an input in determining net income. Cash paid in settlement of contingent consideration liabilities are classified as cash flows from financing activities up to the acquisition date fair value with any excess classified as cash flows from operating activities. Changes in the fair value of contingent consideration liabilities associated with the acquisition of a business can result from updates to assumptions such as the expected timing or probability of achieving customer related performance targets, specified sales milestones, changes in projected revenue or changes in discount rates. Judgment is used in determining those assumptions as of the acquisition date and for each subsequent reporting period. Therefore, any changes in the fair value will impact the Company’s results of operations in such reporting period thereby resulting in potential variability in the Company’s operating results until such contingencies are resolved. Fair Value of Financial Instruments The Company defines fair value as the amount that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. The Company follows accounting guidance that has a three-level hierarchy for fair value measurements based upon the transparency of inputs to the valuation of the asset or liability as of the measurement date. Instruments with readily available actively quoted prices, or for which fair value can be measured from actively quoted prices in an orderly market, will generally have a higher degree of market price transparency and a lesser degree of judgment used in measuring fair value. The three levels of the hierarchy are defined as follows: Level 1—Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets; Level 2—Include other inputs that are directly or indirectly observable in the marketplace; and Level 3—Unobservable inputs which are supported by little or no market activity. As of June 30, 2022 and December 31, 2021, the carrying value of the Company’s current assets and liabilities approximated fair value due to the short maturities of these instruments. The fair values of the Company’s long-term debt approximated carrying value, excluding the effect of unamortized debt discount, as it is based on borrowing rates currently available to the Company for debt with similar terms and maturities (Level 2 inputs). Acquisitions The Company evaluates mergers, acquisitions and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or an acquisition of assets. The Company first identifies who is the acquiring entity by determining if the target is a legal entity or a group of assets or liabilities. If control over a legal entity is being evaluated, the Company also evaluates if the target is a variable interest or voting interest entity. For acquisitions of voting interest entities, the Company applies a screen test to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen test is met, the transaction is accounted for as an acquisition of assets. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs which would meet the definition of a business. The Company accounts for its business combinations using the acquisition method of accounting which requires that the assets acquired and liabilities assumed of acquired businesses be recorded at their respective fair values at the date of acquisition. The purchase price, which includes the fair value of consideration transferred, is attributed to the fair value of the assets acquired and liabilities assumed. The purchase price may also include contingent consideration. The Company assesses whether such contingent consideration is subject to liability classification and fair value measurement or meets the definition of a derivative. Contingent consideration liabilities are recognized at their estimated fair value on the acquisition date. Contingent consideration arrangements that are determined to be compensatory in nature are recognized as post combination expense in our condensed consolidated statements of income ratably over the implied service period beginning in the period it becomes probable such amounts will become payable. The excess of the purchase price of the acquisition over the fair value of the identifiable net assets of the acquiree is recorded as goodwill. The fair value of assets acquired and liabilities assumed in certain cases may be subject to revision based on the final determination of fair value during a period of time not to exceed twelve months from the acquisition date. The results of acquired businesses are included in the Company’s consolidated financial statements from the date of acquisition. Transaction costs directly attributable to acquired businesses are expensed as incurred. Determining the fair value of assets acquired and liabilities assumed requires management to use significant judgment and estimates, including the selection of valuation methodologies and assumptions about future net cash flows, discount rates and market participants. Each of these factors can significantly affect the value attributed to the identifiable intangible asset acquired in a business combination. Concentration of Credit Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash and accounts receivable. The Company maintains substantially all of its cash balances at a financial institution that management believes is of high credit-quality and is financially stable. Cash is deposited with major financial institutions in excess of Federal Deposit Insurance Corporation (“FDIC”) insurance limits. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash is held. The Company provides credit, in the normal course of business, to international and domestic distributors and customers, which are geographically dispersed. The Company attempts to limit its credit risk by performing ongoing credit evaluations of its customers and maintaining adequate allowances for potential credit losses. The following table summarizes revenue from each of our customers who individually accounted for 10% or more of our total revenue or accounts receivable for the periods presented: Revenue Accounts Receivable, net Three Months Ended June 30, Six Months Ended June 30, June 30, 2022 December 31, 2021 2022 2021 2022 2021 BioNTech SE 32.7 % 44.8 % 36.7 % 35.6 % * * Pfizer Inc. 32.1 % 18.1 % 30.9 % 22.6 % 64.2 % 23.6 % CureVac N.V. * * * * * 46.5 % Nacalai USA, Inc. * * * * * 11.6 % ____________________ * Less than 10% For the three and six months ended June 30, 2022 and 2021, substantially all of the revenue recorded for BioNTech SE and Pfizer Inc. was generated by the Nucleic Acid Production segment. Retrospective Application of a Change in Accounting Principle The Company adopted Accounting Standards Codification (“ASC”) 842, Leases (“ASC 842”), which supersedes the guidance in ASC 840, Leases (“ASC 840”), effective January 1, 2021. As the Company elected the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the Jumpstart Our Business Startups Act of 2012, ASC 842 was not adopted until the fourth quarter of 2021. The comparative information for the three and six months ended June 30, 2021 has been adjusted to reflect the impact of the adoption of ASC 842 as of January 1, 2021. Select line items from the condensed consolidated statements of income reflecting the adoption of ASC 842 are as follows (in thousands): Three Months Ended June 30, 2021 As Previously Reported Adjustments As Adjusted Operating expenses: Cost of revenue $ 37,513 $ 298 $ 37,811 Selling, general and administrative 24,085 415 24,500 Resear

Acquisition

Acquisition	6 Months Ended
	Jun. 30, 2022
Business Combination and Asset Acquisition [Abstract]
Acquisition	Acquisition MyChem, LLC On January 27, 2022, the Company completed the acquisition of MyChem, LLC (“MyChem”), a privately-held San Diego, California-based provider of ultra-pure nucleotides to customers in the diagnostics, pharma, genomics and research markets. The acquisition will vertically integrate the Company’s supply chain and expand its product offerings for inputs used in the development of therapeutics and vaccines. The Company acquired MyChem for a total purchase consideration of $257.8 million, subject to customary post-closing adjustments, including a working capital settlement. The total cash consideration paid at closing was $240.0 million using existing cash on hand. The transaction was accounted for as an acquisition of a business as MyChem consisted of inputs and processes applied to those inputs that had the ability to contribute to the creation of outputs. For the three and six months ended June 30, 2022, the Company incurred $0.4 million and $3.4 million, respectively, in transaction costs associated with the acquisition of MyChem, which were recorded within selling, general and administrative in the condensed consolidated statements of income. The acquisition date fair value of consideration transferred to acquire MyChem consisted of the following (in thousands): Cash paid $ 240,012 Consideration payable 10,000 Fair value of contingent consideration 7,800 Total consideration transferred $ 257,812 Pursuant to the Securities Purchase Agreement (the “MyChem SPA”) between the Company and sellers of MyChem, additional payments to the sellers of MyChem are dependent upon meeting or exceeding defined revenue targets during fiscal 2022 (the “Performance Payment”). The MyChem SPA provides for a total maximum Performance Payment of $40.0 million. The MyChem SPA also provides that the Company will pay to the sellers of MyChem an additional $20.0 million (the “Retention Payment”) as of the second anniversary of the closing of the acquisition date as long as two senior employees who are also the sellers of MyChem continue to be employed by TriLink. The Company considers the payment of the Retention Payment as probable and is recognizing compensation expense related to this payment in the post-acquisition period ratably over the expected service period of two years. The MyChem SPA further provides that the Company will pay to the sellers of MyChem an additional amount of up to $10.0 million subject to the completion of certain calculations associated with acquired inventory, which has been recorded within accrued expenses and other current liabilities on the condensed consolidated balance sheet as of June 30, 2022. The Performance Payment was recorded as contingent consideration and was included as part of the purchase consideration. For the three and six months ended June 30, 2022, the Company recorded $2.5 million and $4.3 million of compensation expense related to the Retention Payment within research and development in the condensed consolidated statements of income. The Company estimated the fair value of the Performance Payment contingent consideration based on a Monte-Carlo simulation model which utilized an income approach. The estimated fair value was based on MyChem revenue projections, expected payout term, volatility and risk adjusted discount rates which are Level 3 inputs (see Note 4). As the Company is in the process of finalizing the evaluation of certain liabilities and assets, the allocation of purchase consideration is preliminary and provisional measurements of certain liabilities and goodwill are subject to change. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the acquisition date (in thousands): Cash $ 1,176 Current assets 2,741 Intangible assets, net 123,360 Other assets 9,288 Total identifiable assets acquired 136,565 Current liabilities (1,123) Other long-term liabilities (8,399) Total liabilities assumed (9,522) Net identifiable assets acquired 127,043 Goodwill 130,769 Net assets acquired $ 257,812 The acquisition was accounted for under the acquisition method of accounting, and therefore, the total purchase price was allocated to the identifiable tangible and intangible assets acquired and the liabilities assumed based on their respective fair values as of the acquisition date. Purchase consideration in excess of the amounts recognized for the net assets acquired was recognized as goodwill. Goodwill is primarily attributable to expanded synergies expected from the acquisition associated with a vertical supply integration. There were no tax impacts associated with the acquisition due to the pass-through income tax treatment of MyChem. All of the goodwill acquired in connection with the acquisition of MyChem was allocated to the Company’s Nucleic Acid Production segment and is deductible to Topco LLC for income tax purposes. Upon closing of the acquisition, approximately $1.0 million was placed into escrow to cover potential working capital adjustments and approximately $12.5 million was placed into escrow to secure certain representations and warranties pursuant to the terms of the purchase agreement. These amounts are included in the total purchase consideration of $257.8 million. Because these amounts held in escrow are not controlled by the Company, they are not included in the accompanying condensed consolidated balance sheet as of June 30, 2022. The following table summarizes the estimated fair values of MyChem’s identifiable intangible assets as of the date of acquisition and their estimated useful lives: Estimated Fair Value Estimated Useful Life Trade Names $ 460 3 Developed Technology 121,000 12 Customer Relationships 1,900 12 Total $ 123,360 The trade name and customer relationship intangible assets are related to MyChem’s name, customer loyalty and customer relationships. The developed technology intangible asset is related to processes and techniques for synthesizing and developing ultra-pure nucleotides. The fair value of these intangible assets was based on MyChem’s projected revenues and were estimated using an income approach, specifically the multi-period excess earnings method. Under the income approach, an intangible asset’s fair value is equal to the present value of future economic benefits to be derived from ownership of the asset. The estimated fair value was developed by discounting future net cash flows to their present value at market-based rates of return utilizing Level 3 inputs. The useful lives for these intangible assets was determined based upon the remaining period for which the assets that are expected to contribute directly or indirectly to future cash flows. Key quantitative assumptions used in the determination of fair value of the developed technology intangible included revenue growth rates ranging from 3.0% to 30.6%, a discount rate of 16.5% and an assumed technical obsolescent curve range of 5.0% to 7.5%. Pursuant to the terms of the MyChem SPA, the Company recognized an indemnification asset of $8.0 million within other assets, which represented the seller’s obligation to reimburse pre-acquisition income tax liabilities assumed in the acquisition and was recorded within other long-term liabilities. During the three months ended June 30, 2022, the Company recorded an adjustment of $1.3 million to the indemnification asset within other expense in the condensed consolidated statements of income. As of June 30, 2022, the carrying value of the indemnification asset was $6.8 million recorded within other assets in the condensed consolidated balance sheet. The carrying value of the remaining assets acquired or liabilities assumed was estimated to equal their fair values based on their short-term nature. These estimates were based on the assumption that the Company believes to be reasonable; however, actual results may differ from these estimates. Revenue and earnings from MyChem included in the Company’s condensed consolidated statements of income since the date of acquisition were immaterial. No proforma revenue or earnings information for the three and six months ended June 30, 2022 and 2021 have been presented as the impact was not determined to be material to the Company’s condensed consolidated revenues and net income for the respective periods.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	6 Months Ended
	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible Assets The Company’s goodwill of $283.5 million and $152.8 million as of June 30, 2022 and December 31, 2021, respectively, represents the excess of purchase consideration over the fair value of assets acquired and liabilities assumed. As of June 30, 2022 and December 31, 2021, the Company had three reporting units, two of which are contained in the Nucleic Acid Production segment. During the first quarter of 2022, the Company recorded goodwill of $130.8 million in connection with the acquisition of MyChem that was completed in January 2022 (see Note 2). The Company has not recognized any goodwill impairment in any of the periods presented. The following table summarizes the activity in the Company’s goodwill by segment for the period presented (in thousands): Nucleic Acid Production Biologics Safety Testing Total Balance as of December 31, 2021 $ 32,838 $ 119,928 $ 152,766 Acquisition 130,769 — 130,769 Balance as of June 30, 2022 $ 163,607 $ 119,928 $ 283,535 Intangible assets are being amortized on a straight-line basis, which reflects the expected pattern in which the economic benefits of the intangible assets are being obtained, over an estimated useful life ranging from 3 to 14 years. The following are components of finite-lived intangible assets and accumulated amortization as of the periods presented: June 30, 2022 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Estimated Useful Life Weighted Average Remaining Amortization Period (in thousands) (in years) (in years) Trade Names $ 7,580 $ 5,382 $ 2,198 3 - 10 3.9 Patents and Developed Technology 288,649 73,908 214,741 10 - 14 10.0 Customer Relationships 21,853 9,639 12,214 10 - 12 6.9 Total $ 318,082 $ 88,929 $ 229,153 9.8 December 31, 2021 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Estimated Useful Life Weighted Average Remaining Amortization Period (in thousands) (in years) (in years) Trade Names $ 7,120 $ 5,012 $ 2,108 5 - 10 2.9 Patents and Developed Technology 167,648 63,465 104,183 5 - 14 8.5 Customer Relationships 19,953 8,673 11,280 10 - 12 6.4 Total $ 194,721 $ 77,150 $ 117,571 8.1 During the first quarter of 2022, the Company recorded intangible assets of $123.4 million in connection with the acquisition of MyChem that was completed in January 2022 (see Note 2). The Company recognized $5.6 million and $10.3 million of amortization expense from intangible assets directly linked with revenue generating activities within cost of revenue in the condensed consolidated statements of income for the three and six months ended June 30, 2022, respectively. The Company recognized $3.1 million and $6.2 million of amortization expense from intangible assets directly linked with revenue generating activities within cost of revenue in the condensed consolidated statements of income for the three and six months ended June 30, 2021, respectively. Amortization expense for intangible assets that are not directly related to sales generating activities of $0.7 million and $1.5 million was recorded as selling, general and administrative expenses for the three and six months ended June 30, 2022, respectively. Amortization expense for intangible assets that are not directly related to sales generating activities of $1.9 million and $3.8 million was recorded as selling, general and administrative expenses for the three and six months ended June 30, 2021, respectively. As of June 30, 2022, the estimated future amortization expense for finite-lived intangible assets were as follows (in thousands): 2022 (remaining six months) $ 12,490 2023 24,812 2024 24,812 2025 24,669 2026 24,432 Thereafter 117,938 Total estimated amortization expense $ 229,153

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The following table summarizes the Company’s financial assets and liabilities that are measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): Fair Value Measurements as of June 30, 2022 Level 1 Level 2 Level 3 Total Assets Interest rate cap $ — $ 5,406 $ — $ 5,406 Assets and liabilities measured at fair value on a recurring basis as of December 31, 2021 were insignificant. Contingent Consideration In connection with the acquisition of MyChem (see Note 2), the Company is required to make contingent payments to the sellers of up to $40.0 million subject to achieving certain revenue thresholds. The preliminary fair value of the liability for the contingent payments recognized upon the acquisition as part of the purchase accounting opening balance sheet totaled $7.8 million. The preliminary fair value of the contingent consideration was determined using a Monte-Carlo simulation-based model discounted to present value. Assumptions used in this calculation are expected revenue, a discount rate of 16.9% and various probability factors. The ultimate settlement of the contingent consideration could deviate from current estimates based on the actual results of these financial measures. The contingent consideration projected year of payment is 2023. This liability is considered to be a Level 3 financial liability that is remeasured each reporting period. Changes in fair value of contingent consideration are recognized as a gain or loss and recorded within change in estimated fair value of contingent consideration in the condensed consolidated statements of income. During the three months ended June 30, 2022, the Company recorded a $7.8 million decrease in the estimated fair value of contingent consideration. This was due to a change in estimate associated with MyChem revenue projections reaching thresholds that would trigger a contingent payment per the MyChem SPA. The following table provides a reconciliation of liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the period presented (in thousands): Contingent Consideration Balance as of December 31, 2021 $ — Contingent consideration related to the acquisition of MyChem 7,800 Change in estimated fair value of contingent consideration (7,800) Balance as of June 30, 2022 $ —

Balance Sheet Components

Balance Sheet Components	6 Months Ended
	Jun. 30, 2022
Inventory Disclosure [Abstract]
Balance Sheet Components	Balance Sheet Components Inventory Inventory consisted of the following as of the periods presented (in thousands): June 30, 2022 December 31, 2021 Raw materials $ 20,311 $ 19,726 Work-in-process 30,067 21,382 Finished goods 9,735 10,449 Total inventory $ 60,113 $ 51,557 Other assets Other assets consisted of the following as of the periods presented (in thousands): June 30, 2022 December 31, 2021 Right-of-use assets $ 47,229 $ 49,095 Prepaid lease payments 9,563 — Indemnification asset (see Note 2) 6,766 — Interest rate cap 5,406 541 Other 3,455 3,815 Total other assets $ 72,419 $ 53,451 Accrued expenses and other current liabilities Accrued expenses and other current liabilities consisted of the following as of the periods presented (in thousands): June 30, 2022 December 31, 2021 Employee related $ 13,186 $ 18,894 Consideration payable (see Note 2) 10,000 — Lease liabilities, current portion 4,311 3,722 Professional services 3,324 2,897 Customer deposits 2,090 2,429 Sales and use tax liability 1,670 1,296 Other 9,060 5,336 Total accrued expenses and other current liabilities $ 43,641 $ 34,574

Government Assistance

Government Assistance	6 Months Ended
	Jun. 30, 2022
Government Assistance [Abstract]
Government Assistance	Government Assistance Cooperative Agreement In May 2022, TriLink entered into a cooperative agreement (the “Cooperative Agreement”) with the U.S. Department of Defense, as represented by the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense on behalf of the Biomedical Advanced Research and Development Authority (“BARDA”), within the U.S. Department of Health and Human Services, to advance the development of domestic manufacturing capabilities and to expand TriLink’s domestic production capacity in its San Diego manufacturing campus (the “Flanders San Diego Facility”) for products critical to the development and manufacture of mRNA vaccines and therapeutics. Pursuant to certain requirements, BARDA awarded TriLink an amount equal to $38.8 million or 50% of the construction and validation costs currently budgeted for the Flanders San Diego Facility. The contract period of performance is May 2022 through December 2023, which is the effective date of the Cooperative Agreement through the anticipated date of completion of construction and validation of manufacturing capacity. Amounts reimbursed are subject to audit and may be recaptured by the U.S. Department of Defense in certain circumstances. The Cooperative Agreement requires the Company to provide the U.S. Government with conditional priority access and certain preferred pricing obligations, for a 10-year period from the completion of the construction project, for the production of a medical countermeasure (or a component thereof) that the Company manufactures in the Flanders San Diego Facility during a declared public health emergency. As of June 30, 2022, the Company had not yet received any reimbursements under the Cooperative Agreement, but has recorded a receivable of $8.6 million with an offset recorded to prepaid lease payments associated with our Flanders San Diego Facility within other assets on the condensed consolidated balance sheet.

Long-Term Debt

Long-Term Debt	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Long-Term Debt	Long-Term Debt Credit Agreement In October 2020, Maravai Intermediate Holdings, LLC (“Intermediate”), a wholly-owned subsidiary of Topco LLC, along with its subsidiaries Vector, TriLink and Cygnus (together with Intermediate, the “Borrowers”), entered into a credit agreement (as amended, the “Credit Agreement”), which provides for a $600.0 million term loan facility, maturing October 2027 (the “Term Loan”), and a $180.0 million revolving credit facility (the “Revolving Credit Facility”). In August 2021, in conjunction with the Company’s divestiture of the Protein Detection segment, the Company transferred, per the existing terms of the Credit Agreement, the portion of the Term Loan held by Vector of $118.4 million to Intermediate in its entirety. This amount was not assumed by Voyager Group Holdings, Inc., the entity that acquired Vector, as part of the divestiture. Total outstanding debt and loan covenant requirements remained unchanged as a result of the divestiture. In January 2022, the Company entered into an amendment (the “Amendment”) to the Credit Agreement to: (i) refinance $544.0 million in aggregate principal amount of first lien term loans initially issued thereunder (the “First Lien Term Loan”) and replace it with a Tranche B Term Loan (the “Tranche B Term Loan”); (ii) replace the London Interbank Offered Rate (“LIBOR”) based interest rate with a Term Secured Overnight Financing Rate (“SOFR”) based rate; and (iii) reduce the interest rate margins applicable to the Term Loan and Revolving Credit Facility under the Credit Agreement. The previous interest rate margin on the facilities was, with respect to each LIBOR-based loan, 3.75% to 4.25% and, with respect to each base rate-based loan, 2.75% to 3.25% (depending, in each case, on consolidated first lien leverage). Following the Amendment, the interest rate margin on the facilities is 3.00%, with respect to each Term SOFR-based loan, and 2.00%, with respect to each base rate-based loan. Further, the Amendment reduces the base rate floor for the term loans from 2.00% to 1.50%, sets the floor for Term SOFR-based term loans at 0.50% and sets the floor for Term SOFR-based revolving loans at 0.00%. No other significant terms under the Credit Agreement were changed in connection with the Amendment. As of June 30, 2022, the interest rate on the Tranche B Term Loan was 3.85% per annum. The Credit Agreement also provides for a $20.0 million limit for letters of credit, which remained unused as of June 30, 2022. Borrowings under the Credit Agreement are unconditionally guaranteed by Topco LLC, together with the existing and future material domestic subsidiaries of Topco LLC (subject to certain exceptions), as specified in the respective guaranty agreements. Borrowings under the Credit Agreement are also secured by a first-priority lien and security interest in substantially all of the assets (subject to certain exceptions) of existing and future material domestic subsidiaries of Topco LLC that are loan parties. The accounting related to entering into the Amendment was evaluated on a creditor-by-creditor basis to determine whether each transaction should be accounted for as a modification or extinguishment. Certain creditors under the First Lien Term Loan did not participate in this refinancing transaction, were repaid their principal and interest of $8.5 million and ceased being creditors of the Company and the repayment of their related outstanding debt balances has been accounted for as an extinguishment of debt. Proceeds of borrowings from new lenders of $8.5 million were accounted for as a new debt financing. The Company recorded a loss on extinguishment of debt of $0.2 million in the accompanying condensed consolidated statements of income during the first quarter of 2022. For the remainder of the creditors, this transaction was accounted for as a modification because the change in present value of cash flows between the two term loans before and after the transaction was less than 10% on a creditor-by-creditor basis. As part of the refinancing, the Company incurred $0.9 million of various costs, of which an insignificant amount was related to an original issuance discount, and were all capitalized in the accompanying balance sheet within long-term debt, and are subject to amortization over the term of the refinanced debt as an adjustment to interest expense using the effective interest method. We also incurred $0.3 million of financing-related fees related to the Revolving Credit Facility. As of June 30, 2022, unamortized debt issuance costs totaled $2.6 million and are recorded as assets within other assets on the accompanying condensed consolidated balance sheet as there is no balance outstanding related to the Revolving Credit Facility. Commencing with the fiscal year ended December 31, 2021, and each fiscal year thereafter, the Credit Agreement requires that we make mandatory prepayments on the Term Loan principal upon certain excess cash flow, subject to certain step-downs based on the Company’s first lien net leverage ratio. The mandatory prepayment shall be reduced to 25% or 0% of the calculated excess cash flow if the first lien net leverage ratio was equal to or less than 4.75:1.00 or 4.25:1.00, respectively, however, no prepayment shall be required to the extent excess cash flow calculated for the respective period is equal to or less than $10.0 million. As of June 30, 2022, the Company’s first lien net leverage ratio was less than 4.25:1.00, thus a prepayment was not required. The Tranche B Term Loan became repayable in quarterly payments of $1.4 million beginning in March 2022, with all remaining outstanding principal due in October 2027. The Tranche B Term Loan includes prepayment provisions that allow the Company, at our option, to repay all or a portion of the principal amount at any time. The Revolving Credit Facility allows the Company to repay and borrow from time to time until October 2025, at which time all amounts borrowed must be repaid. Subject to certain exceptions and limitations, we are required to repay borrowings under the Tranche B Term Loan and Revolving Credit Facility with the proceeds of certain occurrences, such as the incurrence of debt, certain equity contributions and certain asset sales or dispositions. Accrued interest under the Credit Agreement is payable by us (a) quarterly in arrears with respect to Base Rate loans, (b) at the end of each interest rate period (or at each three-month interval in the case of loans with interest periods greater than three months) with respect to Term SOFR Rate loans, (c) on the date of any repayment or prepayment and (d) at maturity (whether by acceleration or otherwise). An annual commitment fee is applied to the daily unutilized amount under the Revolving Credit Facility at 0.375% per annum, with one stepdown to 0.25% per annum based on Intermediate’s first lien net leverage ratio. The Credit Agreement contains certain covenants, including, among other things, covenants limiting our ability to incur or prepay certain indebtedness, pay dividends or distributions, dispose of assets, engage in mergers and consolidations, make acquisitions or other investments and make changes in the nature of the business. Additionally, the Credit Agreement also requires us to maintain a certain net leverage ratio. The Company was in compliance with these covenants as of June 30, 2022. Interest Rate Cap In the first quarter of 2021, the Company entered into an interest rate cap agreement to manage a portion of its variable interest rate risk on its outstanding long-term debt. The contract, which was effective March 31, 2021, entitles the Company to receive from the counterparty at each calendar quarter end the amount, if any, by which a specified defined floating market rate exceeds the cap strike interest rate, applied to the contract’s notional amount of $415.0 million The floating rate of interest is reset at the end of each three-month period. The contract was set to expire on March 31, 2023. In May 2022, the Company amended the interest rate cap agreement, effective June 30, 2022, to increase the contract’s notional amount to $500.0 million and to extend the maturity date to January 19, 2025. Additionally, the floating rate option changed from a LIBOR-based rate to a SOFR-based rate. Other provisions remained unchanged as a result of the amendment. Premiums paid to amend the interest rate cap agreement were immaterial. The interest rate cap agreement has not been designated as a hedging relationship and has been recognized on the condensed consolidated balance sheet at fair value of $5.4 million within other assets with changes in fair value recognized within interest expense in the condensed consolidated statements of income. The Company’s long-term debt consisted of the following as of (in thousands): June 30, 2022 December 31, 2021 Tranche B Term Loan $ 541,280 $ — First Lien Term Loan — 544,000 Unamortized debt issuance costs (12,185) (13,409) Total long-term debt 529,095 530,591 Less: current portion (5,440) (6,000) Total long-term debt, less current portion $ 523,655 $ 524,591 There were no balances outstanding on the Company’s Revolving Credit Facility as of June 30, 2022 and December 31, 2021. As of June 30, 2022, the aggregate future principal maturities of the Company’s debt obligations for each of the next five years, based on contractual due dates, were as follows (in thousands): 2022 (remaining six months) $ 2,720 2023 5,440 2024 5,440 2025 5,440 2026 5,440 Thereafter 516,800 Total long-term debt $ 541,280

Net Income Per Class A Common S

Net Income Per Class A Common Share Attributable to Maravai LifeSciences Holdings, Inc.	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Net Income Per Class A Common Share Attributable to Maravai LifeSciences Holdings, Inc.	Net Income Per Class A Common Share Attributable to Maravai LifeSciences Holdings, Inc.Basic net income per Class A common stock has been calculated by dividing net income for the period, adjusted for net income attributable to non-controlling interests, by the weighted average Class A common stock outstanding during the period. Diluted net income per Class A common share gives effect to potentially dilutive securities by application of the treasury stock method or if-converted method, as applicable. Diluted net income per share of Class A common stock attributable to the Company is computed by adjusting the net income and the weighted-average number of shares of Class A common stock outstanding to give effect to potentially diluted securities. The following table presents the computation of basic and diluted net income per common share attributable to the Company for the periods presented (in thousands, except per share amounts): Three Months Ended Six Months Ended 2022 2021 2022 2021 Net income per Class A common share: Numerator—basic: Net income $ 156,721 $ 134,497 $ 303,581 $ 209,962 Less: income attributable to common non-controlling interests (85,481) (85,354) (165,479) (137,717) Net income attributable to Maravai LifeSciences Holdings, Inc.—basic $ 71,240 $ 49,143 $ 138,102 $ 72,245 Numerator—diluted: Net income attributable to Maravai LifeSciences Holdings, Inc.—basic $ 71,240 $ 49,143 $ 138,102 $ 72,245 Net income effect of dilutive securities: Effect of dilutive employee stock purchase plan ("ESPP"), restricted stock units (“RSUs”) and stock options $ 43 $ 19 $ 74 $ 21 Effect of the assumed conversion of Class B common stock 65,256 — 126,327 104,665 Net income attributable to Maravai LifeSciences Holdings, Inc.—diluted $ 136,539 $ 49,162 $ 264,503 $ 176,931 Denominator—basic: Weighted average Class A common shares outstanding—basic 131,524 112,203 131,506 104,468 Net income per Class A common share—basic $ 0.54 $ 0.44 $ 1.05 $ 0.69 Denominator—diluted: Weighted average Class A common shares outstanding—basic 131,524 112,203 131,506 104,468 Weighted average effect of dilutive securities: Effect of dilutive ESPP, RSUs and stock options 168 77 149 52 Effect of the assumed conversion of Class B common stock 123,669 — 123,669 153,166 Weighted average Class A common shares outstanding—diluted 255,361 112,280 255,324 257,686 Net income per Class A common share—diluted $ 0.53 $ 0.44 $ 1.03 $ 0.69 ____________________ * As adjusted to reflect the impact of the adoption of ASC 842. See Note 1 for a summary of the adjustments. Shares of Class B common stock do not share in the earnings or losses of the Company and are therefore not participating securities. As such, a separate presentation of basic and diluted net income per share for Class B common stock under the two-class method has not been presented. The following table presents potentially dilutive securities excluded from the computation of diluted net income per share for the periods presented because their effect would have been anti-dilutive for the periods presented (in thousands): Three Months Ended Six Months Ended 2022 2021 2022 2021 Stock options 2,063 1,619 2,064 1,631 Shares estimated to be purchased under the ESPP 55 25 52 17 Shares of Class B common stock — 143,308 — — 2,118 144,952 2,116 1,648

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Income TaxesWe are subject to U.S. federal and state income taxes with respect to our allocable share of any taxable income or loss of Topco LLC, as well as any stand-alone income or loss we generate. Topco LLC is organized as a limited liability company and treated as a partnership for federal tax purposes and generally does not pay income taxes on its taxable income in most jurisdictions. Instead, Topco LLC’s taxable income or loss is passed through to its members, including us. The following table summarizes the Company’s income tax expense and effective tax rate for the periods presented (in thousands, except percentages): Three Months Ended Six Months Ended 2022 2021 2022 2021 Income before income taxes $ 174,992 $ 145,883 $ 341,833 $ 235,057 Income tax expense $ 18,271 $ 11,386 $ 38,252 $ 25,095 Effective tax rate 10.4 % 7.8 % 11.2 % 10.7 % ____________________ * As adjusted to reflect the impact of the adoption of ASC 842. See Note 1 for a summary of the adjustments. The Company’s effective tax rate of 10.4% and 11.2% for the three and six months ended June 30, 2022, respectively, differed from the U.S. federal statutory rate of 21.0%, primarily due to income associated with the non-controlling interest. The Company’s effective tax rate of 7.8% and 10.7% for the three and six months ended June 30, 2021, respectively, differed from the U.S. federal statutory rate of 21.0%, primarily due to income associated with the non-controlling interest, nondeductible expense related to the Tax Receivable Agreement, and a provisional tax benefit of $2.8 million recorded for the book-tax outside basis difference on Vector due to it meeting the held-for-sale criteria at June 30, 2021. Tax Distributions to Topco LLC’s Owners Topco LLC is subject to an operating agreement put in place at the date of the Organizational Transactions (“LLC Operating Agreement”). The LLC Operating Agreement has numerous provisions related to allocations of income and loss, as well as timing and amounts of distributions to its owners. This agreement also includes a provision requiring cash distributions enabling its owners to pay their taxes on income passing through from Topco LLC. These tax distributions are computed based on an assumed income tax rate equal to the sum of (i) the maximum combined marginal federal and state income tax rate applicable to an individual and (ii) the net investment income tax. The assumed income tax rate currently totals 46.7%, which may increase to 54.1% in certain cases where the qualified business income deduction is unavailable. In addition, under the tax rules, Topco LLC is required to allocate taxable income disproportionately to its unit holders. Because tax distributions are determined based on the holder of LLC Units who is allocated the largest amount of taxable income on a per unit basis, but are made pro rata based on ownership, Topco LLC is required to make tax distributions that, in the aggregate, will likely exceed the amount of taxes Topco LLC would have otherwise paid if it were taxed on its taxable income at the assumed income tax rate. Topco LLC is subject to entity level taxation in certain states and certain of its subsidiaries are subject to entity level U.S. and foreign income taxes. As a result, the accompanying condensed consolidated statements of income include income tax expense related to those states and to U.S. and foreign jurisdictions where Topco LLC or any of our subsidiaries are subject to income tax. During the three months ended June 30, 2022, Topco LLC paid tax distributions of $88.2 million to its owners, including $45.5 million to us. During the six months ended June 30, 2022, Topco LLC paid tax distributions of $170.5 million to its owners, including $87.9 million to us. During the three months ended June 30, 2021, Topco LLC paid tax distributions of $59.5 million to its owners, including $26.4 million to us. During the six months ended June 30, 2021, Topco LLC paid tax distributions of $96.5 million to its owners, including $40.3 million to us. As of June 30, 2022, no amounts for tax distributions had been accrued as such payments were made during the period.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2022
Related Party Transactions [Abstract]
Related Party Transactions	Related Party TransactionsMLSH 1’s majority owner is GTCR, LLC (“GTCR”). The Company’s Chief Executive Officer (“CEO”), Chief Financial Officer (“CFO”) and General Counsel are executives of MLSH 1 and MLSH 2. Payable to Related Parties Pursuant to the Tax Receivable Agreement We are a party to a Tax Receivable Agreement (“TRA”) with MLSH 1 and MLSH 2. The TRA provides for the payment by us to MLSH 1 and MLSH 2, collectively, of 85% of the amount of certain tax benefits, if any, that we actually realize, or in some circumstances are deemed to realize, as a result of the Organizational Transactions, IPO and any subsequent purchases or exchanges of LLC Units of Topco LLC. Based on our current projections of taxable income, and before deduction of any specially allocated depreciation and amortization, we anticipate having enough taxable income to utilize most of these tax benefits. As of June 30, 2022, our liability under the TRA is $746.0 million payable to MLSH 1 and MLSH 2, representing approximately 85% of the calculated tax savings we anticipate being able to utilize in future years. During the six months ended June 30, 2022, the Company recognized a gain of $2.3 million on TRA liability adjustment reflecting a change in the tax benefit obligation attributable to a change in the expected tax benefit. The remeasurement was primarily due to changes in our estimated state apportionment and the corresponding reduction of our estimated state tax rate. During the three and six months ended June 30, 2022, no payments were made to MLSH 1 or MLSH 2 pursuant to the TRA. Topco LLC Operating Agreement MLSH 1 is party to the LLC Operating Agreement put in place at the date of the Organizational Transactions. This agreement includes a provision requiring cash distributions enabling its owners to pay their taxes on income passing through from Topco LLC. During the three and six months ended June 30, 2022 the Company made distributions of $42.6 million and $82.5 million, respectively, for tax liabilities to MLSH 1 under this agreement. During the three and six months ended June 30, 2021, the Company made distributions of $33.1 million and $56.2 million, respectively, for tax liabilities to MLSH 1 under this agreement. Contract Development and Manufacturing Agreement with Curia Global GTCR has significant influence over Curia Global (“Curia”). During the three and six months ended June 30, 2022, the Company paid insignificant amounts to Curia for contract manufacturing and development services. During the three and six months ended June 30, 2021, the Company paid $6.1 million and $6.6 million to Curia, respectively. Such amounts were included in research and development expense on the condensed consolidated statements of income.

Segments

Segments	6 Months Ended
	Jun. 30, 2022
Segment Reporting [Abstract]
Segments	Segments The Company’s financial performance is reported in three segments. A description of each segment follows: • Nucleic Acid Production : focuses on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. This segment also provides research products for labeling and detecting proteins in cells and tissue samples. • Biologics Safety Testing : focuses on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by our customers in their biologic drug manufacturing spectrum. • Protein Detection : focused on manufacturing and selling labeling and visual detection reagents to scientific research customers for their tissue-based protein detection and characterization needs. The Company completed the divestiture of its Protein Detection business in September 2021. The Company has determined that adjusted earnings before interest, tax, depreciation and amortization (“Adjusted EBITDA”) is the profit or loss measure that the CODM uses to make resource allocation decisions and evaluate segment performance. Adjusted EBITDA assists management in comparing the segment performance on a consistent basis for purposes of business decision-making by removing the impact of certain items that management believes do not directly reflect the core operations and, therefore, are not included in measuring segment performance. The Company defines Adjusted EBITDA as net income before interest, taxes, depreciation and amortization, certain non-cash items and other adjustments that we do not consider in our evaluation of ongoing operating performance from period to period. Corporate costs, net of eliminations are managed on a standalone basis and are not allocated to segments. The following schedule includes revenue and adjusted EBITDA for each of the Company’s reportable operating segments (in thousands). We have revised our presentation for the prior periods below to remove the presentation of Total Adjusted EBITDA and reconcile the total of our reportable segments’ measure of profit or loss to income before income taxes in addition to net income, and removed corporate costs, net of eliminations from total reportable segments’ adjusted EBITDA and included such amounts in the reconciliation to income before income taxes. Additionally, we have revised our prior years’ presentation of our total reportable segments’ revenue, in which we removed intersegment eliminations from our total reportable segment’s revenue. Three Months Ended Six Months Ended 2022 2021 2022 2021 Revenue: Nucleic Acid Production $ 225,255 $ 192,738 $ 448,905 $ 316,907 Biologics Safety Testing 17,484 18,208 38,127 35,857 Protein Detection — 7,046 — 13,676 Total reportable segments’ revenue 242,739 217,992 487,032 366,440 Intersegment eliminations (7) (217) (7) (454) Total $ 242,732 $ 217,775 $ 487,025 $ 365,986 Segment adjusted EBITDA: Nucleic Acid Production $ 186,291 $ 156,320 $ 369,090 $ 251,352 Biologics Safety Testing 14,102 14,293 30,634 28,580 Protein Detection — 3,375 — 5,334 Total reportable segments’ adjusted EBITDA 200,393 173,988 399,724 285,266 Reconciliation of total reportable segments’ adjusted EBITDA to income before income taxes Amortization (6,252) (5,040) (11,779) (10,081) Depreciation (1,892) (1,615) (3,747) (2,871) Interest expense (4,434) (7,649) (7,098) (15,553) Corporate costs, net of eliminations (11,914) (9,610) (24,253) (19,992) Other adjustments: Acquisition contingent consideration 7,800 — 7,800 — Acquisition integration costs (3,103) (13) (7,882) (17) Stock-based compensation (4,308) (2,383) (7,935) (4,661) Merger and acquisition related expenses (7) (943) (1,195) (1,862) Financing costs (27) (852) (1,064) (1,058) Acquisition related tax adjustment (1,264) — (1,264) — Tax Receivable Agreement liability adjustment — — 2,340 5,886 Other — — (1,814) — Income before income taxes 174,992 145,883 341,833 235,057 Income tax expense (18,271) (11,386) (38,252) (25,095) Net income $ 156,721 $ 134,497 $ 303,581 $ 209,962 ____________________ * As adjusted to reflect the impact of the adoption of ASC 842. See Note 1 for a summary of the adjustments. During the three and six months ended June 30, 2022, intersegment revenue was immaterial between the Nucleic Acid Production and Biologics Safety Testing segments. During the three and six months ended June 30, 2021, intersegment revenue was $0.2 million and $0.5 million, respectively, between the Nucleic Acid Production and Protein Detection segments. The intersegment sales and the related gross margin on inventory recorded at the end of the period are eliminated for consolidation purposes. Internal selling prices for intersegment sales are consistent with the segment’s normal retail price offered to external parties. There was no commission expense recognized for intersegment sales for the three and six months ended June 30, 2022 and 2021. The Company does not allocate assets to its reportable segments as they are not included in the review performed by the CODM for purposes of assessing segment performance and allocating resources.

Subsequent Event

Subsequent Event	6 Months Ended
	Jun. 30, 2022
Subsequent Events [Abstract]
Subsequent Event	Subsequent EventIn July 2022, the Company entered into a facility lease agreement for additional office, warehouse and light lab space in San Diego, California. The lease term began in July 2022 and will end in September 2026. The lease includes annual base rent payable between $1.9 million and $2.2 million.

Organization and Significant _2

Organization and Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The Company operates and controls all of the business and affairs of Topco LLC, and through Topco LLC and its subsidiaries, conducts its business. Because we manage and operate the business and control the strategic decisions and day-to-day operations of Topco LLC and also have a substantial financial interest in Topco LLC, we consolidate the financial results of Topco LLC, and a portion of our net income is allocated to the non-controlling interests in Topco LLC held by MLSH 1. The accompanying unaudited interim condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany transactions and accounts between the businesses comprising the Company have been eliminated in the accompanying consolidated financial statements.
Unaudited Interim Condensed Consolidated Financial Statements and Non-Controlling Interests	Unaudited Interim Condensed Consolidated Financial Statements The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and pursuant to Form 10-Q of Regulation S-X of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These unaudited condensed consolidated financial statements include all adjustments necessary to fairly state the financial position and the results of our operations and cash flows for interim periods in accordance with GAAP. All such adjustments are of a normal, recurring nature. Operating results for the three and six months ended June 30, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022 or for any future period. The condensed consolidated balance sheet presented as of December 31, 2021, has been derived from the audited consolidated financial statements as of that date. The condensed consolidated financial statements and notes are presented as permitted by Form 10-Q and do not contain all information that is included in the annual financial statements and notes thereto of the Company. The condensed consolidated financial statements and notes included in this report should be read in conjunction with
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in accordance with GAAP requires the Company to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenue and expenses, and related disclosures. These estimates form the basis for judgments the Company makes about the carrying values of assets and liabilities that are not readily apparent from other sources. The Company bases its estimates and judgments on historical experience and on various other assumptions that the Company believes are reasonable under the circumstances. These estimates are based on management’s knowledge about current events and expectations about actions the Company may undertake in the future. Significant estimates include, but are not limited to the payable to related parties pursuant to the Tax Receivable Agreement (as defined in Note 10), the realizability of our net deferred tax assets, and valuation of goodwill and intangible assets acquired in business combinations. Actual results could differ materially from those estimates.
Revenue Recognition	Revenue Recognition The Company generates revenue primarily from the sale of products, and to a much lesser extent, services in the fields of nucleic acid production, biologics safety testing and protein detection. Revenue is recognized when control of promised goods or services is transferred to a customer in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for its arrangements with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The majority of the Company’s contracts include only one performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is defined as the unit of account for revenue recognition. The Company also recognizes revenue from other contracts that may include a combination of products and services, the provision of solely services, or from license fee arrangements which may be associated with the delivery of product. Where there is a combination of products and services, the Company accounts for the promises as individual performance obligations if they are concluded to be distinct. Performance obligations are considered distinct if they are both capable of being distinct and distinct within the context of the contract. In determining whether performance obligations meet the criteria for being distinct, the Company considers a number of factors, such as the degree of interrelation and interdependence between obligations, and whether or not the good or service significantly modifies or transforms another good or service in the contract. As a practical expedient, we do not adjust the transaction price for the effects of a significant financing component if, at contract inception, the period between customer payment and the transfer of goods or services is expected to be one year or less. Contracts with customers are evaluated on a contract-by-contract basis as contracts may include multiple types of goods and services as described below. Nucleic Acid Production Nucleic Acid Production revenue is generated from the manufacture and sale of highly modified, complex nucleic acids products to support the needs of our of customers’ research, therapeutic and vaccine programs. The primary offering of products includes CleanCap®, mRNA and specialized oligonucleotides. Contracts typically consist of a single performance obligation. We also sell nucleic acid products for labeling and detecting proteins in cells and tissue samples research. The Company recognizes revenue from these products in the period in which the performance obligation is satisfied by transferring control to the customer. Revenue for nucleic acid catalog products is recognized at a single point in time, generally upon shipment to the customer. Revenue for contracts for certain custom nucleic acid products, with an enforceable right to payment and a reasonable margin for work performed to date, is recognized over time, based on a cost-to-cost input method over the manufacturing period. Payments received from customers in advance of manufacturing their products is recorded as deferred revenue until the products were delivered. Biologics Safety Testing The Company’s Biologics Safety Testing revenue is associated with the sale of bioprocess impurity detection kit products. We also enter into contracts that include custom antibody development, assay development and antibody affinity extraction services. These products and services enable the detection of impurities that occur in the manufacturing of biologic drugs and other therapeutics. The Company recognizes revenue from the sale of bioprocess impurity detection kits in the period in which the performance obligation is satisfied by transferring control to the customer. Custom antibody development contracts consist of a single performance obligation, typically with an enforceable right to payment and a reasonable margin for work performed to date. Revenue is recognized over time based on a cost-to-cost input method over the contract term. Where an enforceable right to payment does not exist, revenue is recognized at a point in time when control is transferred to the customer. Assay development service contracts consist of a single performance obligation, revenue is recognized at a point in time when a successful antigen test and report is provided to the customer. Affinity extraction services, which generally occur over a short period of time, consist of a single performance obligation to perform the extraction service and provide a summary report to the customer. Revenue is recognized either over time or at a point in time depending on contractual payment terms with the customer. Protein Detection Prior to the divestiture of its Protein Detection business in September 2021, the Company also manufactured and sold protein labeling and detection reagents to customers that were used for basic research and development. The contracts to sell these catalog products consisted of a single performance obligation to deliver the reagent products. Revenue from these contracts was recognized at a point in time, generally upon shipment of the final product to the customer. The Company elected the practical expedient to not disclose the unfulfilled performance obligations for contracts with an original length of one year or less. The Company had no material unfulfilled performance obligations for contracts with an original length greater than one year for any period presented. The Company accepts returns only if the products do not meet customer specifications and historically, the Company’s volume of product returns has not been significant. Further, no warranties are provided for promised goods and services other than assurance type warranties. Revenue for an individual contract is recognized at the related transaction price, which is the amount the Company expects to be entitled to in exchange for transferring the products and/or services. The transaction price for product sales is calculated at the contracted product selling price. The transaction price for a contract with multiple performance obligations is allocated to the separate performance obligations on a relative standalone selling price basis. Standalone selling prices for products are determined based on the prices charged to customers, which are directly observable. Standalone selling price of services are mostly based on time and materials. Generally, payments from customers are due when goods and services are transferred. As most contracts contain a single performance obligation, the transaction price is representative of the standalone selling price charged to customers. Revenue is recognized only to the extent that it is probable that a significant reversal of the cumulative amount recognized will not occur in future periods. Variable consideration has not been material to our consolidated financial statements. Sales taxes Sales taxes collected by the Company are not included in the transaction price as revenue as they are ultimately remitted to a governmental authority. Shipping and handling costs The Company has elected to account for shipping and handling activities related to contracts with customers as costs to fulfill the promise to transfer the associated products. Accordingly, revenue for shipping and handling is recognized at the same time that the related product revenue is recognized. Contract costs The Company recognizes the incremental costs of obtaining contracts as an expense when incurred when the amortization period of the assets that otherwise would have been recognized is one year or less. These costs are included in sales and marketing and general and administrative expenses. The costs to fulfill the contracts are determined to be immaterial and are recognized as an expense when incurred. Contract balances Contract assets are generated when contractual billing schedules differ from revenue recognition timing and the Company records a contract receivable when it has an unconditional right to consideration. There were no contract asset balances as of June 30, 2022 and December 31, 2021.
Segment Information	Segment Information The Company has historically operated in three reportable segments. Operating segments are defined as components of an enterprise for which separate financial information is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and assessing performance. The Company’s chief operating decision maker (“CODM”), its Chief Executive Officer, allocates resources and assesses performance based upon discrete financial information at the segment level. All of our long-lived assets are located in the United States. After the divestiture of Vector in September 2021, the Company no longer has the Protein Detection segment. The Company has reported the historical results of the Protein Detection business as such discrete financial information evaluated by the CODM for the periods presented included the information for this legacy segment. As of June 30, 2022, the Company operated in two reportable segments: Nucleic Acid Production and Biologics Safety Testing.
Net Income per Class A Common Share Attributable to Maravai LifeSciences Holdings, Inc.	Net Income per Class A Common Share Attributable to Maravai LifeSciences Holdings, Inc. Basic net income per Class A common share attributable to Maravai LifeSciences Holdings, Inc. is computed by dividing net income attributable to us by the weighted average number of Class A common shares outstanding during the period. Diluted net income per Class A common share is calculated by giving effect to all potential weighted average dilutive stock options, restricted stock units, and Topco LLC Units, that together with an equal number of shares of our Class B common stock , are convertible into shares of our Class A common stock. The dilutive effect of outstanding awards, if any, is reflected in diluted earnings per share by application of the treasury stock method or if-converted method, as applicable. The Company reported net income attributable to Maravai LifeSciences Holdings, Inc. for the three and six months ended June 30, 2022 and 2021.
Government Assistance	Government Assistance The consideration awarded to the Company by the U.S. Department of Defense is outside the scope of the contracts with customers, income tax, funded research and development, and contribution guidance. This is because the awarding entity is not considered to be a customer, the receipt of the funding is not predicated on the Company’s income tax position, there are no
Contingent Consideration and Acquisitions	Contingent Consideration Contingent consideration represents additional consideration that may be transferred to former owners of an acquired entity in the future if certain future events occur or conditions are met. Contingent consideration resulting from the acquisition of a business is recorded at fair value on the acquisition date. Such contingent consideration is re-measured to its estimated fair value at each reporting date with the change in fair value recognized within operating expenses in the Company’s condensed consolidated statements of income. Subsequent changes in the fair value of the contingent consideration are classified as an adjustment to cash flows from operating activities in the condensed consolidated statements of cash flows because the change in fair value is an input in determining net income. Cash paid in settlement of contingent consideration liabilities are classified as cash flows from financing activities up to the acquisition date fair value with any excess classified as cash flows from operating activities. Changes in the fair value of contingent consideration liabilities associated with the acquisition of a business can result from updates to assumptions such as the expected timing or probability of achieving customer related performance targets, specified sales milestones, changes in projected revenue or changes in discount rates. Judgment is used in determining those assumptions as of the acquisition date and for each subsequent reporting period. Therefore, any changes in the fair value will impact the Company’s results of operations in such reporting period thereby resulting in potential variability in the Company’s operating results until such contingencies are resolved. Acquisitions The Company evaluates mergers, acquisitions and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or an acquisition of assets. The Company first identifies who is the acquiring entity by determining if the target is a legal entity or a group of assets or liabilities. If control over a legal entity is being evaluated, the Company also evaluates if the target is a variable interest or voting interest entity. For acquisitions of voting interest entities, the Company applies a screen test to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen test is met, the transaction is accounted for as an acquisition of assets. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs which would meet the definition of a business. The Company accounts for its business combinations using the acquisition method of accounting which requires that the assets acquired and liabilities assumed of acquired businesses be recorded at their respective fair values at the date of acquisition. The purchase price, which includes the fair value of consideration transferred, is attributed to the fair value of the assets acquired and liabilities assumed. The purchase price may also include contingent consideration. The Company assesses whether such contingent consideration is subject to liability classification and fair value measurement or meets the definition of a derivative. Contingent consideration liabilities are recognized at their estimated fair value on the acquisition date. Contingent consideration arrangements that are determined to be compensatory in nature are recognized as post combination expense in our condensed consolidated statements of income ratably over the implied service period beginning in the period it becomes probable such amounts will become payable. The excess of the purchase price of the acquisition over the fair value of the identifiable net assets of the acquiree is recorded as goodwill. The fair value of assets acquired and liabilities assumed in certain cases may be subject to revision based on the final determination of fair value during a period of time not to exceed twelve months from the acquisition date. The results of acquired businesses are included in the Company’s consolidated financial statements from the date of acquisition. Transaction costs directly attributable to acquired businesses are expensed as incurred. Determining the fair value of assets acquired and liabilities assumed requires management to use significant judgment and estimates, including the selection of valuation methodologies and assumptions about future net cash flows, discount rates and market participants. Each of these factors can significantly affect the value attributed to the identifiable intangible asset acquired in a business combination.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company defines fair value as the amount that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. The Company follows accounting guidance that has a three-level hierarchy for fair value measurements based upon the transparency of inputs to the valuation of the asset or liability as of the measurement date. Instruments with readily available actively quoted prices, or for which fair value can be measured from actively quoted prices in an orderly market, will generally have a higher degree of market price transparency and a lesser degree of judgment used in measuring fair value. The three levels of the hierarchy are defined as follows: Level 1—Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets; Level 2—Include other inputs that are directly or indirectly observable in the marketplace; and Level 3—Unobservable inputs which are supported by little or no market activity. As of June 30, 2022 and December 31, 2021, the carrying value of the Company’s current assets and liabilities approximated fair value due to the short maturities of these instruments. The fair values of the Company’s long-term debt approximated carrying value, excluding the effect of unamortized debt discount, as it is based on borrowing rates currently available to the Company for debt with similar terms and maturities (Level 2 inputs).
Concentration of Credit Risk	Concentration of Credit RiskFinancial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash and accounts receivable. The Company maintains substantially all of its cash balances at a financial institution that management believes is of high credit-quality and is financially stable. Cash is deposited with major financial institutions in excess of Federal Deposit Insurance Corporation (“FDIC”) insurance limits. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash is held. The Company provides credit, in the normal course of business, to international and domestic distributors and customers, which are geographically dispersed. The Company attempts to limit its credit risk by performing ongoing credit evaluations of its customers and maintaining adequate allowances for potential credit losses.
Retrospective Application of a Change in Accounting Principle and Recently Adopted Accounting Pronouncements	Retrospective Application of a Change in Accounting Principle The Company adopted Accounting Standards Codification (“ASC”) 842, Leases (“ASC 842”), which supersedes the guidance in ASC 840, Leases (“ASC 840”), effective January 1, 2021. As the Company elected the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the Jumpstart Our Business Startups Act of 2012, ASC 842 was not adopted until the fourth quarter of 2021. The comparative information for the three and six months ended June 30, 2021 has been adjusted to reflect the impact of the adoption of ASC 842 as of January 1, 2021. Recently Adopted Accounting Pronouncements In November 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2021-10, Government Assistance (Topic 832) - Disclosures by Business Entities about Government Assistance (“ASU 2021-10”). ASU 2021-10 provides guidance to increase the transparency of government assistance including the disclosure of: (i) the types of assistance, (ii) an entity’s accounting for the assistance, and (iii) the effect of the assistance on an entity’s financial statements. Under the new guidance, an entity is required to provide the following annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy: (i) information about the nature of the transactions and the related accounting policy used to account for the transactions, (ii) the line items on the balance sheet and income statement that are affected by the transactions, and the amounts applicable to each financial statement line item, and (iii) significant terms and conditions of the transactions, including commitments and contingencies. The new guidance is required to be adopted either: (i) prospectively to all transactions within the scope of the amendments that are reflected in financial statements at the date of initial application and new transactions that are entered into after the date of initial application, or (ii) retrospectively to those transactions. The Company adopted ASU 2021-10 on January 1, 2022 using the prospective method and is complying with the related disclosure requirements (see Note 6). In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805) - Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”), which requires an acquirer in a business combination to recognize and measure contract assets and contract liabilities in accordance with ASC 606, Revenue from Contracts with Customers, as if it had originated the contracts. This approach differs from the current requirement to measure contract assets and contract liabilities acquired in a business combination at fair value. ASU 2021-08 is effective for years beginning after December 31, 2022, including interim periods within those fiscal years, with early adoption permitted. The ASU is to be applied prospectively to business combinations occurring on or after the effective date of its adoption. The Company early adopted ASU 2021-08 and there was no impact to the Company’s condensed consolidated financial statements as a result of the adoption of this ASU.

Organization and Significant _3

Organization and Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Summary of Revenue by Geographic Areas and Segment	The following tables summarize the revenue by segment and region for the periods presented (in thousands): Three Months Ended June 30, 2022 Nucleic Acid Production Biologics Safety Testing Total North America $ 82,015 $ 7,172 $ 89,187 Europe, the Middle East and Africa 113,461 4,578 118,039 Asia Pacific 29,737 5,605 35,342 Latin and Central America 35 129 164 Total revenue $ 225,248 $ 17,484 $ 242,732 Six Months Ended June 30, 2022 Nucleic Acid Production Biologics Safety Testing Total North America $ 161,433 $ 14,691 $ 176,124 Europe, the Middle East and Africa 244,811 9,275 254,086 Asia Pacific 42,604 13,933 56,537 Latin and Central America 50 228 278 Total revenue $ 448,898 $ 38,127 $ 487,025 Three Months Ended June 30, 2021 Nucleic Acid Production Biologics Safety Testing Protein Detection Total North America $ 65,715 $ 6,437 $ 4,197 $ 76,349 Europe, the Middle East and Africa 106,046 3,899 1,892 111,837 Asia Pacific 20,760 7,668 913 29,341 Latin and Central America — 204 44 248 Total revenue $ 192,521 $ 18,208 $ 7,046 $ 217,775 Six Months Ended June 30, 2021 Nucleic Acid Production Biologics Safety Testing Protein Detection Total North America $ 133,847 $ 12,849 $ 7,949 $ 154,645 Europe, the Middle East and Africa 153,944 8,248 3,360 165,552 Asia Pacific 28,645 14,403 2,273 45,321 Latin and Central America 17 357 94 468 Total revenue $ 316,453 $ 35,857 $ 13,676 $ 365,986
Summary of Concentration of Revenue	The following table summarizes revenue from each of our customers who individually accounted for 10% or more of our total revenue or accounts receivable for the periods presented: Revenue Accounts Receivable, net Three Months Ended June 30, Six Months Ended June 30, June 30, 2022 December 31, 2021 2022 2021 2022 2021 BioNTech SE 32.7 % 44.8 % 36.7 % 35.6 % * * Pfizer Inc. 32.1 % 18.1 % 30.9 % 22.6 % 64.2 % 23.6 % CureVac N.V. * * * * * 46.5 % Nacalai USA, Inc. * * * * * 11.6 % ____________________ * Less than 10%
Summary of Accounting Standards Update Impact	Select line items from the condensed consolidated statements of income reflecting the adoption of ASC 842 are as follows (in thousands): Three Months Ended June 30, 2021 As Previously Reported Adjustments As Adjusted Operating expenses: Cost of revenue $ 37,513 $ 298 $ 37,811 Selling, general and administrative 24,085 415 24,500 Research and development 1,932 (3) 1,929 Total operating expenses 63,530 710 64,240 Income from operations 154,245 (710) 153,535 Other income (expense): Interest expense (8,512) 863 (7,649) Income before income taxes 145,730 153 145,883 Net income 134,344 153 134,497 Net income attributable to non-controlling interests 85,269 85 85,354 Net income attributable to Maravai LifeSciences Holdings, Inc. 49,075 68 49,143 Six Months Ended June 30, 2021 As Previously Reported Adjustments As Adjusted Operating expenses: Cost of revenue $ 67,881 $ 1,321 $ 69,202 Selling, general and administrative 47,322 649 47,971 Research and development 4,096 (7) 4,089 Total operating expenses 119,299 1,963 121,262 Income from operations 246,687 (1,963) 244,724 Other income (expense): Interest expense (17,282) 1,729 (15,553) Income before income taxes 235,291 (234) 235,057 Net income 210,196 (234) 209,962 Net income attributable to non-controlling interests 137,874 (157) 137,717 Net income attributable to Maravai LifeSciences Holdings, Inc. 72,322 (77) 72,245 Select line items from the condensed consolidated statements of comprehensive income reflecting the adoption of ASC 842 are as follows (in thousands): Three Months Ended June 30, 2021 As Previously Reported Adjustments As Adjusted Net income $ 134,344 $ 153 $ 134,497 Total other comprehensive income 134,352 153 134,505 Comprehensive income attributable to non-controlling interests 85,274 85 85,359 Total comprehensive income attributable to Maravai LifeSciences Holdings, Inc. 49,078 68 49,146 Six Months Ended June 30, 2021 As Previously Reported Adjustments As Adjusted Net income $ 210,196 $ (234) $ 209,962 Total other comprehensive income 210,212 (234) 209,978 Comprehensive income attributable to non-controlling interests 137,885 (157) 137,728 Total comprehensive income attributable to Maravai LifeSciences Holdings, Inc. 72,327 (77) 72,250 Select line items from the condensed consolidated statements of changes in stockholders’ equity reflecting the adoption of ASC 842 are as follows (in thousands): As of June 30, 2021 As Previously Reported Adjustments As Adjusted Additional paid-in capital $ 118,208 $ 278 $ 118,486 Retained earnings 73,176 1,593 74,769 Non-controlling interest 139,220 2,349 141,569 Total stockholders' equity 333,141 4,220 337,361 Select line items from the condensed consolidated statements of cash flows reflecting the adoption of ASC 842 are as follows (in thousands): Six Months Ended June 30, 2021 As Previously Reported Adjustments As Adjusted Operating activities Net income $ 210,196 $ (234) $ 209,962 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation 4,151 (1,280) 2,871 Amortization of right-of-use assets — 3,510 3,510 Non-cash interest expense recognized on lease facility financing obligation 162 (162) — Other (389) 288 (101) Changes in operating assets and liabilities: Inventory (18,073) (421) (18,494) Prepaid expenses and other assets (5,013) (57) (5,070) Accounts payable 4,085 76 4,161 Accrued expenses and other current liabilities (13,916) 1,372 (12,544) Other long-term liabilities (1) (3,374) (3,375) Net cash provided by operating activities 204,547 (282) 204,265 Investing activities Purchases of property and equipment (7,782) (83) (7,865) Net cash used in investing activities (7,234) (83) (7,317) Financing activities Payments made on facility financing lease obligation and capital lease (365) 365 — Net cash used in financing activities (58,550) 365 (58,185)

Acquisition (Tables)

Acquisition (Tables)	6 Months Ended
	Jun. 30, 2022
Business Combination and Asset Acquisition [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The acquisition date fair value of consideration transferred to acquire MyChem consisted of the following (in thousands): Cash paid $ 240,012 Consideration payable 10,000 Fair value of contingent consideration 7,800 Total consideration transferred $ 257,812 Cash $ 1,176 Current assets 2,741 Intangible assets, net 123,360 Other assets 9,288 Total identifiable assets acquired 136,565 Current liabilities (1,123) Other long-term liabilities (8,399) Total liabilities assumed (9,522) Net identifiable assets acquired 127,043 Goodwill 130,769 Net assets acquired $ 257,812
Summary of Intangible Assets Acquired	The following table summarizes the estimated fair values of MyChem’s identifiable intangible assets as of the date of acquisition and their estimated useful lives: Estimated Fair Value Estimated Useful Life Trade Names $ 460 3 Developed Technology 121,000 12 Customer Relationships 1,900 12 Total $ 123,360

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Goodwill	The following table summarizes the activity in the Company’s goodwill by segment for the period presented (in thousands): Nucleic Acid Production Biologics Safety Testing Total Balance as of December 31, 2021 $ 32,838 $ 119,928 $ 152,766 Acquisition 130,769 — 130,769 Balance as of June 30, 2022 $ 163,607 $ 119,928 $ 283,535
Components of Finite-Lived Intangible Assets	The following are components of finite-lived intangible assets and accumulated amortization as of the periods presented: June 30, 2022 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Estimated Useful Life Weighted Average Remaining Amortization Period (in thousands) (in years) (in years) Trade Names $ 7,580 $ 5,382 $ 2,198 3 - 10 3.9 Patents and Developed Technology 288,649 73,908 214,741 10 - 14 10.0 Customer Relationships 21,853 9,639 12,214 10 - 12 6.9 Total $ 318,082 $ 88,929 $ 229,153 9.8 December 31, 2021 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Estimated Useful Life Weighted Average Remaining Amortization Period (in thousands) (in years) (in years) Trade Names $ 7,120 $ 5,012 $ 2,108 5 - 10 2.9 Patents and Developed Technology 167,648 63,465 104,183 5 - 14 8.5 Customer Relationships 19,953 8,673 11,280 10 - 12 6.4 Total $ 194,721 $ 77,150 $ 117,571 8.1
Schedule of Finite-Lived Intangible Assets Future Amortization Expense	As of June 30, 2022, the estimated future amortization expense for finite-lived intangible assets were as follows (in thousands): 2022 (remaining six months) $ 12,490 2023 24,812 2024 24,812 2025 24,669 2026 24,432 Thereafter 117,938 Total estimated amortization expense $ 229,153

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Schedule of Fair Value of Assets Measured on Recurring Basis	The following table summarizes the Company’s financial assets and liabilities that are measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): Fair Value Measurements as of June 30, 2022 Level 1 Level 2 Level 3 Total Assets Interest rate cap $ — $ 5,406 $ — $ 5,406
Schedule of Business Acquisitions by Acquisition, Contingent Consideration	The following table provides a reconciliation of liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the period presented (in thousands): Contingent Consideration Balance as of December 31, 2021 $ — Contingent consideration related to the acquisition of MyChem 7,800 Change in estimated fair value of contingent consideration (7,800) Balance as of June 30, 2022 $ —

Balance Sheet Components (Table

Balance Sheet Components (Tables)	6 Months Ended
	Jun. 30, 2022
Inventory Disclosure [Abstract]
Summary of Inventory	Inventory consisted of the following as of the periods presented (in thousands): June 30, 2022 December 31, 2021 Raw materials $ 20,311 $ 19,726 Work-in-process 30,067 21,382 Finished goods 9,735 10,449 Total inventory $ 60,113 $ 51,557
Schedule of Other Assets	Other assets consisted of the following as of the periods presented (in thousands): June 30, 2022 December 31, 2021 Right-of-use assets $ 47,229 $ 49,095 Prepaid lease payments 9,563 — Indemnification asset (see Note 2) 6,766 — Interest rate cap 5,406 541 Other 3,455 3,815 Total other assets $ 72,419 $ 53,451
Summary of Accrued Expenses	Accrued expenses and other current liabilities consisted of the following as of the periods presented (in thousands): June 30, 2022 December 31, 2021 Employee related $ 13,186 $ 18,894 Consideration payable (see Note 2) 10,000 — Lease liabilities, current portion 4,311 3,722 Professional services 3,324 2,897 Customer deposits 2,090 2,429 Sales and use tax liability 1,670 1,296 Other 9,060 5,336 Total accrued expenses and other current liabilities $ 43,641 $ 34,574

Long-Term Debt (Tables)

Long-Term Debt (Tables)	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Summary of Long-Term Debt	The Company’s long-term debt consisted of the following as of (in thousands): June 30, 2022 December 31, 2021 Tranche B Term Loan $ 541,280 $ — First Lien Term Loan — 544,000 Unamortized debt issuance costs (12,185) (13,409) Total long-term debt 529,095 530,591 Less: current portion (5,440) (6,000) Total long-term debt, less current portion $ 523,655 $ 524,591
Schedule of Maturities of Long-Term Debt	As of June 30, 2022, the aggregate future principal maturities of the Company’s debt obligations for each of the next five years, based on contractual due dates, were as follows (in thousands): 2022 (remaining six months) $ 2,720 2023 5,440 2024 5,440 2025 5,440 2026 5,440 Thereafter 516,800 Total long-term debt $ 541,280

Net Income Per Class A Common_2

Net Income Per Class A Common Share Attributable to Maravai LifeSciences Holdings, Inc. (Tables)	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Earnings Per Share	The following table presents the computation of basic and diluted net income per common share attributable to the Company for the periods presented (in thousands, except per share amounts): Three Months Ended Six Months Ended 2022 2021 2022 2021 Net income per Class A common share: Numerator—basic: Net income $ 156,721 $ 134,497 $ 303,581 $ 209,962 Less: income attributable to common non-controlling interests (85,481) (85,354) (165,479) (137,717) Net income attributable to Maravai LifeSciences Holdings, Inc.—basic $ 71,240 $ 49,143 $ 138,102 $ 72,245 Numerator—diluted: Net income attributable to Maravai LifeSciences Holdings, Inc.—basic $ 71,240 $ 49,143 $ 138,102 $ 72,245 Net income effect of dilutive securities: Effect of dilutive employee stock purchase plan ("ESPP"), restricted stock units (“RSUs”) and stock options $ 43 $ 19 $ 74 $ 21 Effect of the assumed conversion of Class B common stock 65,256 — 126,327 104,665 Net income attributable to Maravai LifeSciences Holdings, Inc.—diluted $ 136,539 $ 49,162 $ 264,503 $ 176,931 Denominator—basic: Weighted average Class A common shares outstanding—basic 131,524 112,203 131,506 104,468 Net income per Class A common share—basic $ 0.54 $ 0.44 $ 1.05 $ 0.69 Denominator—diluted: Weighted average Class A common shares outstanding—basic 131,524 112,203 131,506 104,468 Weighted average effect of dilutive securities: Effect of dilutive ESPP, RSUs and stock options 168 77 149 52 Effect of the assumed conversion of Class B common stock 123,669 — 123,669 153,166 Weighted average Class A common shares outstanding—diluted 255,361 112,280 255,324 257,686 Net income per Class A common share—diluted $ 0.53 $ 0.44 $ 1.03 $ 0.69 ____________________ * As adjusted to reflect the impact of the adoption of ASC 842. See Note 1 for a summary of the adjustments.
Summary of Dilutive Securities Excluded from Computation of Earnings Per Share	The following table presents potentially dilutive securities excluded from the computation of diluted net income per share for the periods presented because their effect would have been anti-dilutive for the periods presented (in thousands): Three Months Ended Six Months Ended 2022 2021 2022 2021 Stock options 2,063 1,619 2,064 1,631 Shares estimated to be purchased under the ESPP 55 25 52 17 Shares of Class B common stock — 143,308 — — 2,118 144,952 2,116 1,648

Income Taxes (Tables)

Income Taxes (Tables)	6 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit)	The following table summarizes the Company’s income tax expense and effective tax rate for the periods presented (in thousands, except percentages): Three Months Ended Six Months Ended 2022 2021 2022 2021 Income before income taxes $ 174,992 $ 145,883 $ 341,833 $ 235,057 Income tax expense $ 18,271 $ 11,386 $ 38,252 $ 25,095 Effective tax rate 10.4 % 7.8 % 11.2 % 10.7 % ____________________ * As adjusted to reflect the impact of the adoption of ASC 842. See Note 1 for a summary of the adjustments.

Segments (Tables)

Segments (Tables)	6 Months Ended
	Jun. 30, 2022
Segment Reporting [Abstract]
Summary of Segment Reporting Information	The following schedule includes revenue and adjusted EBITDA for each of the Company’s reportable operating segments (in thousands). We have revised our presentation for the prior periods below to remove the presentation of Total Adjusted EBITDA and reconcile the total of our reportable segments’ measure of profit or loss to income before income taxes in addition to net income, and removed corporate costs, net of eliminations from total reportable segments’ adjusted EBITDA and included such amounts in the reconciliation to income before income taxes. Additionally, we have revised our prior years’ presentation of our total reportable segments’ revenue, in which we removed intersegment eliminations from our total reportable segment’s revenue. Three Months Ended Six Months Ended 2022 2021 2022 2021 Revenue: Nucleic Acid Production $ 225,255 $ 192,738 $ 448,905 $ 316,907 Biologics Safety Testing 17,484 18,208 38,127 35,857 Protein Detection — 7,046 — 13,676 Total reportable segments’ revenue 242,739 217,992 487,032 366,440 Intersegment eliminations (7) (217) (7) (454) Total $ 242,732 $ 217,775 $ 487,025 $ 365,986 Segment adjusted EBITDA: Nucleic Acid Production $ 186,291 $ 156,320 $ 369,090 $ 251,352 Biologics Safety Testing 14,102 14,293 30,634 28,580 Protein Detection — 3,375 — 5,334 Total reportable segments’ adjusted EBITDA 200,393 173,988 399,724 285,266 Reconciliation of total reportable segments’ adjusted EBITDA to income before income taxes Amortization (6,252) (5,040) (11,779) (10,081) Depreciation (1,892) (1,615) (3,747) (2,871) Interest expense (4,434) (7,649) (7,098) (15,553) Corporate costs, net of eliminations (11,914) (9,610) (24,253) (19,992) Other adjustments: Acquisition contingent consideration 7,800 — 7,800 — Acquisition integration costs (3,103) (13) (7,882) (17) Stock-based compensation (4,308) (2,383) (7,935) (4,661) Merger and acquisition related expenses (7) (943) (1,195) (1,862) Financing costs (27) (852) (1,064) (1,058) Acquisition related tax adjustment (1,264) — (1,264) — Tax Receivable Agreement liability adjustment — — 2,340 5,886 Other — — (1,814) — Income before income taxes 174,992 145,883 341,833 235,057 Income tax expense (18,271) (11,386) (38,252) (25,095) Net income $ 156,721 $ 134,497 $ 303,581 $ 209,962 ____________________ * As adjusted to reflect the impact of the adoption of ASC 842. See Note 1 for a summary of the adjustments.
Reconciliation of Revenue	The following schedule includes revenue and adjusted EBITDA for each of the Company’s reportable operating segments (in thousands). We have revised our presentation for the prior periods below to remove the presentation of Total Adjusted EBITDA and reconcile the total of our reportable segments’ measure of profit or loss to income before income taxes in addition to net income, and removed corporate costs, net of eliminations from total reportable segments’ adjusted EBITDA and included such amounts in the reconciliation to income before income taxes. Additionally, we have revised our prior years’ presentation of our total reportable segments’ revenue, in which we removed intersegment eliminations from our total reportable segment’s revenue. Three Months Ended Six Months Ended 2022 2021 2022 2021 Revenue: Nucleic Acid Production $ 225,255 $ 192,738 $ 448,905 $ 316,907 Biologics Safety Testing 17,484 18,208 38,127 35,857 Protein Detection — 7,046 — 13,676 Total reportable segments’ revenue 242,739 217,992 487,032 366,440 Intersegment eliminations (7) (217) (7) (454) Total $ 242,732 $ 217,775 $ 487,025 $ 365,986 Segment adjusted EBITDA: Nucleic Acid Production $ 186,291 $ 156,320 $ 369,090 $ 251,352 Biologics Safety Testing 14,102 14,293 30,634 28,580 Protein Detection — 3,375 — 5,334 Total reportable segments’ adjusted EBITDA 200,393 173,988 399,724 285,266 Reconciliation of total reportable segments’ adjusted EBITDA to income before income taxes Amortization (6,252) (5,040) (11,779) (10,081) Depreciation (1,892) (1,615) (3,747) (2,871) Interest expense (4,434) (7,649) (7,098) (15,553) Corporate costs, net of eliminations (11,914) (9,610) (24,253) (19,992) Other adjustments: Acquisition contingent consideration 7,800 — 7,800 — Acquisition integration costs (3,103) (13) (7,882) (17) Stock-based compensation (4,308) (2,383) (7,935) (4,661) Merger and acquisition related expenses (7) (943) (1,195) (1,862) Financing costs (27) (852) (1,064) (1,058) Acquisition related tax adjustment (1,264) — (1,264) — Tax Receivable Agreement liability adjustment — — 2,340 5,886 Other — — (1,814) — Income before income taxes 174,992 145,883 341,833 235,057 Income tax expense (18,271) (11,386) (38,252) (25,095) Net income $ 156,721 $ 134,497 $ 303,581 $ 209,962 ____________________ * As adjusted to reflect the impact of the adoption of ASC 842. See Note 1 for a summary of the adjustments.

Organization and Significant _4

Organization and Significant Accounting Policies - Description of Business (Details)	6 Months Ended
	Jun. 30, 2022 segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of operating segments	3

Organization and Significant _5

Organization and Significant Accounting Policies - Revenue Recognition (Details) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Contract assets	$ 0	$ 0
Contract liabilities	$ 7,500,000	$ 12,600,000

Organization and Significant _6

Organization and Significant Accounting Policies - Geographical Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021		Jun. 30, 2022	Jun. 30, 2021
Disaggregation of Revenue [Line Items]
Revenue	$ 242,732	$ 217,775	[1]	$ 487,025	$ 365,986	[1]
North America
Disaggregation of Revenue [Line Items]
Revenue	89,187	76,349		176,124	154,645
Europe, the Middle East and Africa
Disaggregation of Revenue [Line Items]
Revenue	118,039	111,837		254,086	165,552
Asia Pacific
Disaggregation of Revenue [Line Items]
Revenue	35,342	29,341		56,537	45,321
Latin and Central America
Disaggregation of Revenue [Line Items]
Revenue	164	248		278	468
Nucleic Acid Production
Disaggregation of Revenue [Line Items]
Revenue	225,248	192,521		448,898	316,453
Nucleic Acid Production | North America
Disaggregation of Revenue [Line Items]
Revenue	82,015	65,715		161,433	133,847
Nucleic Acid Production | Europe, the Middle East and Africa
Disaggregation of Revenue [Line Items]
Revenue	113,461	106,046		244,811	153,944
Nucleic Acid Production | Asia Pacific
Disaggregation of Revenue [Line Items]
Revenue	29,737	20,760		42,604	28,645
Nucleic Acid Production | Latin and Central America
Disaggregation of Revenue [Line Items]
Revenue	35	0		50	17
Biologics Safety Testing
Disaggregation of Revenue [Line Items]
Revenue	17,484	18,208		38,127	35,857
Biologics Safety Testing | North America
Disaggregation of Revenue [Line Items]
Revenue	7,172	6,437		14,691	12,849
Biologics Safety Testing | Europe, the Middle East and Africa
Disaggregation of Revenue [Line Items]
Revenue	4,578	3,899		9,275	8,248
Biologics Safety Testing | Asia Pacific
Disaggregation of Revenue [Line Items]
Revenue	5,605	7,668		13,933	14,403
Biologics Safety Testing | Latin and Central America
Disaggregation of Revenue [Line Items]
Revenue	$ 129	204		$ 228	357
Protein Detection
Disaggregation of Revenue [Line Items]
Revenue		7,046			13,676
Protein Detection | North America
Disaggregation of Revenue [Line Items]
Revenue		4,197			7,949
Protein Detection | Europe, the Middle East and Africa
Disaggregation of Revenue [Line Items]
Revenue		1,892			3,360
Protein Detection | Asia Pacific
Disaggregation of Revenue [Line Items]
Revenue		913			2,273
Protein Detection | Latin and Central America
Disaggregation of Revenue [Line Items]
Revenue		$ 44			$ 94
[1]As adjusted to reflect the impact of the adoption of Accounting Standards Codification 842 (“ASC 842”). See Note 1 to the condensed consolidated financial statements for a summary of the adjustments.

Organization and Significant _7

Organization and Significant Accounting Policies - Non-Controlling Interests (Details)	6 Months Ended
	Jun. 30, 2022
Noncontrolling Interest [Line Items]
Stock conversion ratio	1
Topco LLC
Noncontrolling Interest [Line Items]
Ownership percent by parent	51.50%
Topco LLC | MLSH 1
Noncontrolling Interest [Line Items]
Ownership percent by noncontrolling interest	48.50%

Organization and Significant _8

Organization and Significant Accounting Policies - Exchange and Secondary Offering (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	3 Months Ended		6 Months Ended
	Apr. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Topco LLC | Tax Distribution
Net income per Class A common share:
Tax distributions paid		$ 88.2	$ 59.5	$ 170.5	$ 96.5
Topco LLC | MLSH 1 | Tax Distribution
Net income per Class A common share:
Tax distributions paid		$ 42.6	$ 33.1	$ 82.5	$ 56.2
Secondary Offering
Net income per Class A common share:
Conversion of LLC units to common stock (in shares)	17,665,959
Issuance of stock (in shares)	20,700,000
Offering cost payments	$ 1
Secondary Offering | MLSH 1
Net income per Class A common share:
Proceeds from issuance of stock	$ 624.2
Secondary Offering By MLSH 2
Net income per Class A common share:
Issuance of stock (in shares)	3,034,041
Over-Allotment Option
Net income per Class A common share:
Issuance of stock (in shares)	2,700,000
Stock issued price (in usd per share)	$ 31.25

Organization and Significant _9

Organization and Significant Accounting Policies - Segment Information (Details) - segment	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of reportable segments	2	3

Organization and Significant_10

Organization and Significant Accounting Policies - Concentration Risk (Details) - Customer Concentration Risk	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Revenue | BioNTech SE
Product Information [Line Items]
Concentration risk	32.70%	44.80%	36.70%	35.60%
Revenue | Pfizer Inc.
Product Information [Line Items]
Concentration risk	32.10%	18.10%	30.90%	22.60%
Accounts Receivable, net | Pfizer Inc.
Product Information [Line Items]
Concentration risk			64.20%		23.60%
Accounts Receivable, net | CureVac N.V.
Product Information [Line Items]
Concentration risk					46.50%
Accounts Receivable, net | Nacalai USA, Inc.
Product Information [Line Items]
Concentration risk					11.60%

Organization and Significant_11

Organization and Significant Accounting Policies - ASU Impact on Income Statement (Details) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021		Jun. 30, 2022	Jun. 30, 2021
Operating expenses:
Cost of revenue	$ 37,496	$ 37,811	[1]	$ 77,528	$ 69,202	[1]
Selling, general and administrative	28,061	24,500	[1]	61,261	47,971	[1]
Research and development	4,274	1,929	[1]	7,969	4,089	[1]
Total operating expenses	62,031	64,240	[1]	138,958	121,262	[1]
Income from operations	180,701	153,535	[1]	348,067	244,724	[1]
Other income (expense):
Interest expense	(4,434)	(7,649)	[1]	(7,098)	(15,553)	[1]
Income before income taxes	174,992	145,883	[1]	341,833	235,057	[1]
Net income	156,721	134,497	[1],[2]	303,581	209,962	[1],[3]
Net income attributable to non-controlling interests	85,481	85,354	[1]	165,479	137,717	[1]
Net income attributable to Maravai LifeSciences Holdings, Inc.	$ 71,240	49,143	[1]	$ 138,102	72,245	[1]
As Previously Reported
Operating expenses:
Cost of revenue		37,513			67,881
Selling, general and administrative		24,085			47,322
Research and development		1,932			4,096
Total operating expenses		63,530			119,299
Income from operations		154,245			246,687
Other income (expense):
Interest expense		(8,512)			(17,282)
Income before income taxes		145,730			235,291
Net income		134,344			210,196
Net income attributable to non-controlling interests		85,269			137,874
Net income attributable to Maravai LifeSciences Holdings, Inc.		49,075			72,322
Adjustments
Operating expenses:
Cost of revenue		298			1,321
Selling, general and administrative		415			649
Research and development		(3)			(7)
Total operating expenses		710			1,963
Income from operations		(710)			(1,963)
Other income (expense):
Interest expense		863			1,729
Income before income taxes		153			(234)
Net income		153			(234)
Net income attributable to non-controlling interests		85			(157)
Net income attributable to Maravai LifeSciences Holdings, Inc.		$ 68			$ (77)
[1]As adjusted to reflect the impact of the adoption of Accounting Standards Codification 842 (“ASC 842”). See Note 1 to the condensed consolidated financial statements for a summary of the adjustments.[2]As adjusted to reflect the impact of the adoption of ASC 842. See Note 1 to the condensed consolidated financial statements for a summary of the adjustments.[3]As adjusted to reflect the impact of the adoption of ASC 842. See Note 1 to the condensed consolidated financial statements for a summary of the adjustments.

Organization and Significant_12

Organization and Significant Accounting Policies - ASU Impact on Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021		Jun. 30, 2022	Jun. 30, 2021
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net income	$ 156,721	$ 134,497	[1],[2]	$ 303,581	$ 209,962	[2],[3]
Total other comprehensive income	156,721	134,505	[1]	303,581	209,978	[1]
Comprehensive income attributable to non-controlling interests	85,481	85,359	[1]	165,479	137,728	[1]
Total comprehensive income attributable to Maravai LifeSciences Holdings, Inc.	$ 71,240	49,146	[1]	$ 138,102	72,250	[1]
As Previously Reported
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net income		134,344			210,196
Total other comprehensive income		134,352			210,212
Comprehensive income attributable to non-controlling interests		85,274			137,885
Total comprehensive income attributable to Maravai LifeSciences Holdings, Inc.		49,078			72,327
Adjustments
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net income		153			(234)
Total other comprehensive income		153			(234)
Comprehensive income attributable to non-controlling interests		85			(157)
Total comprehensive income attributable to Maravai LifeSciences Holdings, Inc.		$ 68			$ (77)
[1]As adjusted to reflect the impact of the adoption of ASC 842. See Note 1 to the condensed consolidated financial statements for a summary of the adjustments.[2]As adjusted to reflect the impact of the adoption of Accounting Standards Codification 842 (“ASC 842”). See Note 1 to the condensed consolidated financial statements for a summary of the adjustments.[3]As adjusted to reflect the impact of the adoption of ASC 842. See Note 1 to the condensed consolidated financial statements for a summary of the adjustments.

Organization and Significant_13

Organization and Significant Accounting Policies - ASU Impact on Stockholders' Equity (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Jun. 30, 2021		Mar. 31, 2021	Dec. 31, 2020
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Additional paid-in capital	$ 131,373		$ 128,386	$ 118,486
Retained earnings	322,663		184,561	74,769
Non-controlling interest	317,204		229,862	141,569
Total stockholders' equity	$ 773,792	$ 654,302	$ 545,361	337,361	[1]	$ 213,823	$ 154,746
As Previously Reported
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Additional paid-in capital				118,208
Retained earnings				73,176
Non-controlling interest				139,220
Total stockholders' equity				333,141
Adjustments
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Additional paid-in capital				278
Retained earnings				1,593
Non-controlling interest				2,349
Total stockholders' equity				$ 4,220
[1]As adjusted to reflect the impact of the adoption of ASC 842. See Note 1 to the condensed consolidated financial statements for a summary of the adjustments.

Organization and Significant_14

Organization and Significant Accounting Policies - ASU Impact on Cash Flow (Details) - USD ($) $ in Thousands		3 Months Ended			6 Months Ended
		Jun. 30, 2022	Jun. 30, 2021		Jun. 30, 2022	Jun. 30, 2021
Operating activities:
Net income		$ 156,721	$ 134,497	[1],[2]	$ 303,581	$ 209,962	[2],[3]
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation		$ 1,892	1,615		3,747	2,871	[3]
Amortization of right-of-use assets					2,639	3,510	[3]
Non-cash interest expense recognized on lease facility financing obligation						0
Other					(1,283)	(101)	[3]
Changes in operating assets and liabilities:
Inventory					(7,502)	(18,494)	[3]
Prepaid expenses and other assets					(10,052)	(5,070)	[3]
Accounts payable					6,310	4,161	[3]
Accrued expenses and other current liabilities					(1,773)	(12,544)	[3]
Other long-term liabilities					759	(3,375)	[3]
Net cash provided by operating activities					326,583	204,265	[3]
Investing activities:
Purchases of property and equipment					(4,409)	(7,865)	[3]
Net cash used in investing activities					(243,245)	(7,317)	[3]
Financing activities:
Payments made on facility financing lease obligation and capital lease	[3]					0
Net cash used in financing activities					$ (83,934)	(58,185)	[3]
As Previously Reported
Operating activities:
Net income			134,344			210,196
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation						4,151
Amortization of right-of-use assets						0
Non-cash interest expense recognized on lease facility financing obligation						162
Other						(389)
Changes in operating assets and liabilities:
Inventory						(18,073)
Prepaid expenses and other assets						(5,013)
Accounts payable						4,085
Accrued expenses and other current liabilities						(13,916)
Other long-term liabilities						(1)
Net cash provided by operating activities						204,547
Investing activities:
Purchases of property and equipment						(7,782)
Net cash used in investing activities						(7,234)
Financing activities:
Payments made on facility financing lease obligation and capital lease						(365)
Net cash used in financing activities						(58,550)
Adjustments
Operating activities:
Net income			$ 153			(234)
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation						(1,280)
Amortization of right-of-use assets						3,510
Non-cash interest expense recognized on lease facility financing obligation						(162)
Other						288
Changes in operating assets and liabilities:
Inventory						(421)
Prepaid expenses and other assets						(57)
Accounts payable						76
Accrued expenses and other current liabilities						1,372
Other long-term liabilities						(3,374)
Net cash provided by operating activities						(282)
Investing activities:
Purchases of property and equipment						(83)
Net cash used in investing activities						(83)
Financing activities:
Payments made on facility financing lease obligation and capital lease						365
Net cash used in financing activities						$ 365
[1]As adjusted to reflect the impact of the adoption of ASC 842. See Note 1 to the condensed consolidated financial statements for a summary of the adjustments.[2]As adjusted to reflect the impact of the adoption of Accounting Standards Codification 842 (“ASC 842”). See Note 1 to the condensed consolidated financial statements for a summary of the adjustments.[3]As adjusted to reflect the impact of the adoption of ASC 842. See Note 1 to the condensed consolidated financial statements for a summary of the adjustments.

Acquisition - Narrative (Detail

Acquisition - Narrative (Details) $ in Thousands		3 Months Ended		6 Months Ended
	Jan. 27, 2022 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)
Business Acquisition [Line Items]
Transaction costs		$ 7	$ 943	$ 1,195	$ 1,862
Contingent consideration		0		0		$ 0
Carrying value of indemnification assets		6,766		6,766		$ 0
MyChem
Business Acquisition [Line Items]
Consideration transferred	$ 257,812
Cash paid	240,012
Transaction costs		400		3,400
Indemnification asset amount	$ 8,000
Adjustments of indemnification assets		1,300
Carrying value of indemnification assets		6,800		6,800
MyChem | Measurement Input, Revenue Growth Rate | Valuation Technique, Discounted Cash Flow | Minimum
Business Acquisition [Line Items]
Intangible assets, measurement input	0.030
MyChem | Measurement Input, Revenue Growth Rate | Valuation Technique, Discounted Cash Flow | Maximum
Business Acquisition [Line Items]
Intangible assets, measurement input	0.306
MyChem | Measurement Input, Discount Rate | Valuation Technique, Discounted Cash Flow
Business Acquisition [Line Items]
Intangible assets, measurement input	0.165
MyChem | Measurement Input, Obsolescent Curve | Valuation Technique, Discounted Cash Flow | Minimum
Business Acquisition [Line Items]
Intangible assets, measurement input	0.050
MyChem | Measurement Input, Obsolescent Curve | Valuation Technique, Discounted Cash Flow | Maximum
Business Acquisition [Line Items]
Intangible assets, measurement input	0.075
MyChem | Potential Working Capital Adjustments
Business Acquisition [Line Items]
Escrow deposit	$ 1,000
MyChem | Secure Representations and Warranties
Business Acquisition [Line Items]
Escrow deposit	$ 12,500
MyChem | MyChem Legacy Owners
Business Acquisition [Line Items]
Service period	2 years
MyChem | SPA, Maximum Performance Payment
Business Acquisition [Line Items]
Contingent consideration	$ 40,000
MyChem | SPA, Retention Payment
Business Acquisition [Line Items]
Contingent consideration	20,000
MyChem | SPA, Retention Payment | MyChem Legacy Owners
Business Acquisition [Line Items]
Compensation expense		$ 2,500		$ 4,300
MyChem | SPA, Completion of Acquired Inventory
Business Acquisition [Line Items]
Contingent consideration	$ 10,000

Acquisition - Summary of Consid

Acquisition - Summary of Consideration Transferred (Details) - MyChem - USD ($) $ in Thousands		6 Months Ended
	Jan. 27, 2022	Jun. 30, 2022
Business Acquisition [Line Items]
Cash paid	$ 240,012
Consideration payable	10,000
Fair value of contingent consideration	7,800	$ 7,800
Total consideration transferred	$ 257,812

Acquisition - Summary of Assets

Acquisition - Summary of Assets and Liabilities Acquired (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Jan. 27, 2022	Dec. 31, 2021
Business Acquisition [Line Items]
Goodwill	$ 283,535		$ 152,766
MyChem
Business Acquisition [Line Items]
Cash		$ 1,176
Current assets		2,741
Intangible assets, net		123,360
Other assets		9,288
Total identifiable assets acquired		136,565
Current liabilities		(1,123)
Other long-term liabilities		(8,399)
Total liabilities assumed		(9,522)
Net identifiable assets acquired		127,043
Goodwill		130,769
Net assets acquired		$ 257,812

Acquisition - Summary of Intang

Acquisition - Summary of Intangible Assets Acquired (Details) - MyChem $ in Thousands	Jan. 27, 2022 USD ($)
Business Acquisition [Line Items]
Intangible assets, net	$ 123,360
Trade Names
Business Acquisition [Line Items]
Intangible assets, net	$ 460
Estimated Useful Life (in years)	3 years
Developed Technology
Business Acquisition [Line Items]
Intangible assets, net	$ 121,000
Estimated Useful Life (in years)	12 years
Customer Relationships
Business Acquisition [Line Items]
Intangible assets, net	$ 1,900
Estimated Useful Life (in years)	12 years

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Narrative (Details) $ in Thousands	3 Months Ended			6 Months Ended			12 Months Ended
	Jun. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) reporting_unit	Jun. 30, 2021 USD ($)		Dec. 31, 2021 USD ($) reporting_unit	Jan. 27, 2022 USD ($)
Finite-Lived Intangible Assets [Line Items]
Goodwill	$ 283,535			$ 283,535			$ 152,766
Number of reporting units | reporting_unit				3			3
Goodwill acquired				$ 130,769
Amortization of intangible assets				11,779	$ 10,081	[1]
MyChem
Finite-Lived Intangible Assets [Line Items]
Goodwill								$ 130,769
Intangible assets, net		$ 123,400
Cost of Revenue
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets	5,600		$ 3,100	10,300	6,200
Selling, General and Administrative Expenses
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets	700		$ 1,900	$ 1,500	$ 3,800
Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated useful life				3 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated useful life				14 years
Nucleic Acid Production
Finite-Lived Intangible Assets [Line Items]
Goodwill	$ 163,607			$ 163,607			$ 32,838
Number of reporting units | reporting_unit				2			2
Goodwill acquired				$ 130,769
Protein Detection
Finite-Lived Intangible Assets [Line Items]
Goodwill acquired		$ 130,800
[1]As adjusted to reflect the impact of the adoption of ASC 842. See Note 1 to the condensed consolidated financial statements for a summary of the adjustments.

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Summary of Segment's Goodwill (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($)
Goodwill [Roll Forward]
Balance as of December 31, 2021	$ 152,766
Goodwill acquired	130,769
Balance as of June 30, 2022	283,535
Nucleic Acid Production
Goodwill [Roll Forward]
Balance as of December 31, 2021	32,838
Goodwill acquired	130,769
Balance as of June 30, 2022	163,607
Biologics Safety Testing
Goodwill [Roll Forward]
Balance as of December 31, 2021	119,928
Goodwill acquired	0
Balance as of June 30, 2022	$ 119,928

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Components of Finite-Lived Intangible Assets (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 318,082	$ 194,721
Accumulated Amortization	88,929	77,150
Net Carrying Amount	$ 229,153	$ 117,571
Weighted Average Remaining Amortization Period	9 years 9 months 18 days	8 years 1 month 6 days
Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life	3 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life	14 years
Trade Names
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 7,580	$ 7,120
Accumulated Amortization	5,382	5,012
Net Carrying Amount	$ 2,198	$ 2,108
Weighted Average Remaining Amortization Period	3 years 10 months 24 days	2 years 10 months 24 days
Trade Names | Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life	3 years	5 years
Trade Names | Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life	10 years	10 years
Patents and Developed Technology
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 288,649	$ 167,648
Accumulated Amortization	73,908	63,465
Net Carrying Amount	$ 214,741	$ 104,183
Weighted Average Remaining Amortization Period	10 years	8 years 6 months
Patents and Developed Technology | Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life	10 years	5 years
Patents and Developed Technology | Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life	14 years	14 years
Customer Relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 21,853	$ 19,953
Accumulated Amortization	9,639	8,673
Net Carrying Amount	$ 12,214	$ 11,280
Weighted Average Remaining Amortization Period	6 years 10 months 24 days	6 years 4 months 24 days
Customer Relationships | Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life	10 years	10 years
Customer Relationships | Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life	12 years	12 years

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets - Expected Amortization of Finite-Lived Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
2022 (remaining six months)	$ 12,490
2023	24,812
2024	24,812
2025	24,669
2026	24,432
Thereafter	117,938
Net Carrying Amount	$ 229,153	$ 117,571

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Recurring Assets (Details) - Fair Value, Recurring $ in Thousands	Jun. 30, 2022 USD ($)
Assets
Derivative assets	$ 5,406
Level 1
Assets
Derivative assets	0
Level 2
Assets
Derivative assets	5,406
Level 3
Assets
Derivative assets	$ 0

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details) $ in Thousands		3 Months Ended			6 Months Ended
	Jan. 27, 2022 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	[1]	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	[1],[2]	Dec. 31, 2021 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration		$ 0			$ 0			$ 0
Decrease in estimated fair value of contingent consideration		7,800	$ 0		7,800	$ 0
MyChem
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of contingent consideration	$ 7,800				$ 7,800
Decrease in estimated fair value of contingent consideration		$ 7,800
MyChem | Measurement Input, Discount Rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration liability, measurement input	0.169
MyChem | SPA, Maximum Performance Payment
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	$ 40,000
[1]As adjusted to reflect the impact of the adoption of Accounting Standards Codification 842 (“ASC 842”). See Note 1 to the condensed consolidated financial statements for a summary of the adjustments.[2]As adjusted to reflect the impact of the adoption of ASC 842. See Note 1 to the condensed consolidated financial statements for a summary of the adjustments.

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Contingent Consideration (Details) - USD ($) $ in Thousands		3 Months Ended			6 Months Ended
	Jan. 27, 2022	Jun. 30, 2022	Jun. 30, 2021	[1]	Jun. 30, 2022	Jun. 30, 2021	[1],[2]
Business Combination, Contingent Consideration, Liability [Roll Forward]
Beginning balance					$ 0
Change in estimated fair value of contingent consideration		$ (7,800)	$ 0		(7,800)	$ 0
Ending balance		0			0
MyChem
Business Combination, Contingent Consideration, Liability [Roll Forward]
Contingent consideration related to the acquisition of MyChem	$ 7,800				$ 7,800
Change in estimated fair value of contingent consideration		$ (7,800)
[1]As adjusted to reflect the impact of the adoption of Accounting Standards Codification 842 (“ASC 842”). See Note 1 to the condensed consolidated financial statements for a summary of the adjustments.[2]As adjusted to reflect the impact of the adoption of ASC 842. See Note 1 to the condensed consolidated financial statements for a summary of the adjustments.

Balance Sheet Components - Inve

Balance Sheet Components - Inventory (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Raw materials	$ 20,311	$ 19,726
Work-in-process	30,067	21,382
Finished goods	9,735	10,449
Total inventory	$ 60,113	$ 51,557

Balance Sheet Components - Othe

Balance Sheet Components - Other Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Right-of-use assets	$ 47,229	$ 49,095
Prepaid lease payments	9,563	0
Indemnification asset	6,766	0
Interest rate cap	5,406	541
Other	3,455	3,815
Other assets	$ 72,419	$ 53,451

Balance Sheet Components - Summ

Balance Sheet Components - Summary of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Employee related	$ 13,186	$ 18,894
Consideration payable	10,000	0
Lease liabilities, current portion	4,311	3,722
Professional services	3,324	2,897
Customer deposits	2,090	2,429
Sales and use tax liability	1,670	1,296
Other	9,060	5,336
Total accrued expenses and other current liabilities	$ 43,641	$ 34,574

Government Assistance (Details)

Government Assistance (Details) - USD ($) $ in Thousands	1 Months Ended
	May 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Gain Contingencies [Line Items]
Government funding receivable		$ 8,575	$ 0
Cooperative Agreement
Gain Contingencies [Line Items]
Expectation of reimbursement amount from government	$ 38,800
Percentage of reimbursable costs	50%
Priority access period	10 years
Government funding receivable		$ 8,600

Long-Term Debt - Narrative (Det

Long-Term Debt - Narrative (Details)

1 Months Ended

3 Months Ended

6 Months Ended

Mar. 31, 2022 USD ($)

Jan. 31, 2022 USD ($)

Oct. 31, 2020 USD ($)

Jun. 30, 2022 USD ($)

Mar. 31, 2022 USD ($)

Jun. 30, 2021 USD ($)

[1]

Jun. 30, 2022 USD ($) loan

Jun. 30, 2021 USD ($)

[1],[2]

May 31, 2022 USD ($)

Dec. 31, 2021 USD ($)

Aug. 31, 2021 USD ($)

Mar. 31, 2021 USD ($)

Jan. 31, 2021 USD ($)

Debt Instrument [Line Items]

Long-term debt

$ 544,000,000

$ 529,095,000

$ 529,095,000

$ 530,591,000

Loss on long-term debt refinancing

0

$ 0

208,000

$ 0

Debt issuance costs

2,600,000

2,600,000

Interest rate cap

5,406,000

5,406,000

541,000

Interest Rate Cap

Debt Instrument [Line Items]

Derivative, notional amount

$ 500,000,000

$ 415,000,000

Interest rate cap

$ 5,400,000

$ 5,400,000

New Credit Agreement

Debt Instrument [Line Items]

Proceeds from debt

8,500,000

Loss on long-term debt refinancing

$ 200,000

Number of term loans | loan

2

New Credit Agreement | Secured Debt

Debt Instrument [Line Items]

Repayments of debt

$ 8,500,000

New Credit Agreement | Line of Credit | London Interbank Offered Rate (LIBOR) | Minimum

Debt Instrument [Line Items]

Basis spread on variable rate

3.75%

New Credit Agreement | Line of Credit | London Interbank Offered Rate (LIBOR) | Maximum

Debt Instrument [Line Items]

Basis spread on variable rate

4.25%

New Credit Agreement | Line of Credit | Base Rate

Debt Instrument [Line Items]

Basis spread on variable rate

2%

New Credit Agreement | Line of Credit | Base Rate | Minimum

Debt Instrument [Line Items]

Basis spread on variable rate

2.75%

New Credit Agreement | Line of Credit | Base Rate | Maximum

Debt Instrument [Line Items]

Basis spread on variable rate

3.25%

New Credit Agreement | Line of Credit | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate

Debt Instrument [Line Items]

Basis spread on variable rate

3%

New Credit Agreement | Line of Credit | Secured Debt

Debt Instrument [Line Items]

Line of credit facility, maximum borrowing capacity

$ 600,000,000

Debt interest rate

3.85%

3.85%

Debt issuance costs

$ 900,000

Leverage ratio covenant

4.25

4.25

Excess cash threshold amount

$ 10,000,000

$ 10,000,000

Periodic payments

$ 1,400,000

Annual commitment fee percentage

0.375%

Stepdown rate

0.25%

New Credit Agreement | Line of Credit | Secured Debt | Intermediate

Debt Instrument [Line Items]

Long-term debt

$ 118,400,000

New Credit Agreement | Line of Credit | Secured Debt | Minimum

Debt Instrument [Line Items]

Excess cash ratio percentage

0%

0%

New Credit Agreement | Line of Credit | Secured Debt | Maximum

Debt Instrument [Line Items]

Excess cash ratio percentage

25%

25%

Leverage ratio covenant

4.75

4.75

New Credit Agreement | Line of Credit | Revolving Credit Facility

Debt Instrument [Line Items]

Line of credit facility, maximum borrowing capacity

$ 180,000,000

Debt issuance costs

$ 300,000

$ 300,000

Outstanding line of credit

$ 0

$ 0

$ 0

New Credit Agreement | Line of Credit | Letter of Credit

Debt Instrument [Line Items]

Line of credit facility, maximum borrowing capacity

$ 20,000,000

Initial Term Loans | Line of Credit | Base Rate

Debt Instrument [Line Items]

Interest rate floor

1.50%

2%

Initial Term Loans | Line of Credit | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate

Debt Instrument [Line Items]

Interest rate floor

0.50%

Non Initial Term Loans | Line of Credit | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate

Debt Instrument [Line Items]

Interest rate floor

0%

[1]As adjusted to reflect the impact of the adoption of Accounting Standards Codification 842 (“ASC 842”). See Note 1 to the condensed consolidated financial statements for a summary of the adjustments.[2]As adjusted to reflect the impact of the adoption of ASC 842. See Note 1 to the condensed consolidated financial statements for a summary of the adjustments.

Long-Term Debt - Summary of Lon

Long-Term Debt - Summary of Long-Term Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Jan. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Long-term debt, gross	$ 541,280
Unamortized debt issuance costs	(12,185)		$ (13,409)
Total long-term debt	529,095	$ 544,000	530,591
Less: current portion	(5,440)		(6,000)
Long-term debt, less current portion	523,655		524,591
Secured Debt | New Credit Agreement
Debt Instrument [Line Items]
Long-term debt, gross	0		544,000
Secured Debt | New Credit Agreement | Line of Credit
Debt Instrument [Line Items]
Long-term debt, gross	$ 541,280		$ 0

Long-Term Debt - Maturities of

Long-Term Debt - Maturities of Long-Term Debt (Details) $ in Thousands	Jun. 30, 2022 USD ($)
Debt Disclosure [Abstract]
2022 (remaining six months)	$ 2,720
2023	5,440
2024	5,440
2025	5,440
2026	5,440
Thereafter	516,800
Long-term debt, gross	$ 541,280

Net Income Per Class A Common_3

Net Income Per Class A Common Share Attributable to Maravai LifeSciences Holdings, Inc. - Summary of Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021		Jun. 30, 2022	Jun. 30, 2021
Numerator—basic:
Net income	$ 156,721	$ 134,497	[1],[2]	$ 303,581	$ 209,962	[2],[3]
Less: income attributable to common non-controlling interests	(85,481)	(85,354)		(165,479)	(137,717)
Net income attributable to Maravai LifeSciences Holdings, Inc.—basic	71,240	49,143		138,102	72,245
Numerator—diluted:
Net income attributable to Maravai LifeSciences Holdings, Inc.—basic	71,240	49,143		138,102	72,245
Net income effect of dilutive securities:
Effect of dilutive employee stock purchase plan ("ESPP"), restricted stock units (“RSUs”) and stock options	43	19		74	21
Effect of the assumed conversion of Class B common stock	65,256	0		126,327	104,665
Net income attributable to Maravai LifeSciences Holdings, Inc.—diluted	$ 136,539	$ 49,162		$ 264,503	$ 176,931
Denominator—basic:
Weighted average Class A common shares outstanding—basic (in shares)	131,524	112,203	[2]	131,506	104,468	[2]
Net income per Class A common share—basic (in usd per share)	$ 0.54	$ 0.44	[2]	$ 1.05	$ 0.69	[2]
Denominator—diluted:
Weighted average Class A common shares outstanding—basic (in shares)	131,524	112,203	[2]	131,506	104,468	[2]
Weighted average effect of dilutive securities:
Effect of dilutive ESPP, RSUs and options (in shares)	168	77		149	52
Effect of the assumed conversion of Class B common stock (in shares)	123,669	0		123,669	153,166
Weighted average Class A common shares outstanding—diluted (in shares)	255,361	112,280	[2]	255,324	257,686	[2]
Net income per Class A common share - diluted (in usd per share)	$ 0.53	$ 0.44	[2]	$ 1.03	$ 0.69	[2]
[1]As adjusted to reflect the impact of the adoption of ASC 842. See Note 1 to the condensed consolidated financial statements for a summary of the adjustments.[2]As adjusted to reflect the impact of the adoption of Accounting Standards Codification 842 (“ASC 842”). See Note 1 to the condensed consolidated financial statements for a summary of the adjustments.[3]As adjusted to reflect the impact of the adoption of ASC 842. See Note 1 to the condensed consolidated financial statements for a summary of the adjustments.

Net Income Per Class A Common_4

Net Income Per Class A Common Share Attributable to Maravai LifeSciences Holdings, Inc. - Summary of Dilutive Securities Excluded (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from computation of net income per share (in shares)	2,118	144,952	2,116	1,648
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from computation of net income per share (in shares)	2,063	1,619	2,064	1,631
Shares estimated to be purchased under the ESPP
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from computation of net income per share (in shares)	55	25	52	17
Class B Common Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from computation of net income per share (in shares)	0	143,308	0	0

Income Taxes - Summary of Incom

Income Taxes - Summary of Income Tax Expense (Details) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021		Jun. 30, 2022	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Income before income taxes	$ 174,992	$ 145,883	[1]	$ 341,833	$ 235,057	[1]
Income tax expense	$ 18,271	$ 11,386	[1]	$ 38,252	$ 25,095	[1]
Effective tax rate	10.40%	7.80%		11.20%	10.70%
[1]As adjusted to reflect the impact of the adoption of Accounting Standards Codification 842 (“ASC 842”). See Note 1 to the condensed consolidated financial statements for a summary of the adjustments.

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Tax Examination [Line Items]
Effective tax rate	10.40%	7.80%	11.20%	10.70%
Assumed income tax rate			46.70%
Assumed income tax rate when business income deduction is unavailable			54.10%
Tax distribution payable	$ 0		$ 0
Topco LLC | Tax Distribution
Income Tax Examination [Line Items]
Tax distributions paid	88,200,000	$ 59,500,000	170,500,000	$ 96,500,000
Topco LLC | Maravai LifeSciences Holdings, Inc | Tax Distribution
Income Tax Examination [Line Items]
Tax distributions paid	$ 45,500,000	$ 26,400,000	$ 87,900,000	40,300,000
Disposal Group, Held-for-sale, Not Discontinued Operations | Vector
Income Tax Examination [Line Items]
Tax benefit				$ 2,800,000

Related Party Transactions - Na

Related Party Transactions - Narrative (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Related Party Transaction [Line Items]
Percentage of tax benefits paid			85%
Liability payable to related party	$ 746,000,000		$ 746,000,000
Gain on tax receivable agreement	0	$ 0	2,340,000	$ 5,886,000	[1]
Distribution	42,653,000	33,075,000	82,542,000	56,203,000
Non-Controlling Interest
Related Party Transaction [Line Items]
Distribution	42,588,000	33,112,000	82,477,000	56,237,000
Affiliated Entity | Tax Receivable Agreement, Payments
Related Party Transaction [Line Items]
Related party transaction amounts	$ 0		$ 0
Affiliated Entity | Consulting Services | Curia Global
Related Party Transaction [Line Items]
Related party transaction expense		$ 6,100,000		$ 6,600,000
[1]As adjusted to reflect the impact of the adoption of ASC 842. See Note 1 to the condensed consolidated financial statements for a summary of the adjustments.

Segments - Narrative (Details)

Segments - Narrative (Details)	3 Months Ended			6 Months Ended			12 Months Ended
	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)		Jun. 30, 2022 USD ($) segment	Jun. 30, 2021 USD ($)		Dec. 31, 2021 segment
Segment Reporting, Revenue Reconciling Item [Line Items]
Number of reportable segments | segment				2			3
Revenue	$ (242,732,000)	$ (217,775,000)	[1]	$ (487,025,000)	$ (365,986,000)	[1]
Intersegment eliminations
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenue	7,000	217,000		7,000	454,000
Commission expense	$ 0	$ 0		$ 0	$ 0
[1]As adjusted to reflect the impact of the adoption of Accounting Standards Codification 842 (“ASC 842”). See Note 1 to the condensed consolidated financial statements for a summary of the adjustments.

Segments - Reconciliation of Re

Segments - Reconciliation of Revenue and Adjusted EBITDA to Net Loss (Details) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021		Jun. 30, 2022	Jun. 30, 2021
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenue	$ 242,732	$ 217,775	[1]	$ 487,025	$ 365,986	[1]
Amortization	(6,252)	(5,040)		(11,779)	(10,081)
Depreciation	(1,892)	(1,615)		(3,747)	(2,871)	[2]
Interest expense	(4,434)	(7,649)	[1]	(7,098)	(15,553)	[1]
Corporate costs, net of eliminations	(11,914)	(9,610)		(24,253)	(19,992)
Other adjustments:
Fair value of contingent consideration liability recorded in connection with acquisition of a business	7,800	0	[1]	7,800	0	[1],[2]
Acquisition integration costs	(3,103)	(13)		(7,882)	(17)
Stock-based compensation	(4,308)	(2,383)		(7,935)	(4,661)
Merger and acquisition related expenses	(7)	(943)		(1,195)	(1,862)
Financing costs	(27)	(852)		(1,064)	(1,058)
Acquisition related tax adjustment	(1,264)	0		(1,264)	0
Tax Receivable Agreement liability adjustment	0	0		2,340	5,886	[2]
Other	0	0		(1,814)	0
Income before income taxes	174,992	145,883	[1]	341,833	235,057	[1]
Income tax expense	(18,271)	(11,386)	[1]	(38,252)	(25,095)	[1]
Net income	156,721	134,497	[1],[3]	303,581	209,962	[1],[2]
Nucleic Acid Production
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenue	225,248	192,521		448,898	316,453
Biologics Safety Testing
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenue	17,484	18,208		38,127	35,857
Protein Detection
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenue		7,046			13,676
Operating Segments
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenue	242,739	217,992		487,032	366,440
Segment adjusted EBITDA	200,393	173,988		399,724	285,266
Operating Segments | Nucleic Acid Production
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenue	225,255	192,738		448,905	316,907
Segment adjusted EBITDA	186,291	156,320		369,090	251,352
Operating Segments | Biologics Safety Testing
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenue	17,484	18,208		38,127	35,857
Segment adjusted EBITDA	14,102	14,293		30,634	28,580
Operating Segments | Protein Detection
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenue	0	7,046		0	13,676
Segment adjusted EBITDA	0	3,375		0	5,334
Intersegment eliminations
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenue	$ (7)	$ (217)		$ (7)	$ (454)
[1]As adjusted to reflect the impact of the adoption of Accounting Standards Codification 842 (“ASC 842”). See Note 1 to the condensed consolidated financial statements for a summary of the adjustments.[2]As adjusted to reflect the impact of the adoption of ASC 842. See Note 1 to the condensed consolidated financial statements for a summary of the adjustments.[3]As adjusted to reflect the impact of the adoption of ASC 842. See Note 1 to the condensed consolidated financial statements for a summary of the adjustments.

Subsequent Event (Details)

Subsequent Event (Details) - Subsequent Event - San Diego Facility Lease $ in Millions	1 Months Ended
	Jul. 31, 2022 USD ($)
Minimum
Subsequent Event [Line Items]
Rent payable	$ 1.9
Maximum
Subsequent Event [Line Items]
Rent payable	$ 2.2

Uncategorized Items - mrvi-2022

Label	Element	Value
Accounting Standards Update [Extensible Enumeration]	us-gaap_AccountingStandardsUpdateExtensibleList	Accounting Standards Update 2016-02 [Member]